



US008476305B2

(12) **United States Patent**  
**Yamamuro et al.**

(10) **Patent No.:** **US 8,476,305 B2**  
(45) **Date of Patent:** **Jul. 2, 2013**

(54) **THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR INFLAMMATORY BOWEL DISEASE COMPRISING AMINO ALCOHOL DERIVATIVE AS ACTIVE INGREDIENT**

(75) Inventors: **Naoya Yamamuro**, Tochigi (JP); **Koichi Nakamaru**, Tochigi (JP); **Tokutarou Yasue**, Tochigi (JP)

(73) Assignee: **Kyorin Pharmaceutical Co., Ltd.**, Tokyo (JP)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 313 days.

(21) Appl. No.: **12/866,576**

(22) PCT Filed: **Feb. 6, 2009**

(86) PCT No.: **PCT/JP2009/052037**

§ 371 (c)(1),  
(2), (4) Date: **Aug. 6, 2010**

(87) PCT Pub. No.: **WO2009/099174**

PCT Pub. Date: **Aug. 13, 2009**

(65) **Prior Publication Data**

US 2010/0324057 A1 Dec. 23, 2010

(30) **Foreign Application Priority Data**

Feb. 7, 2008 (JP) ..... P2008-028070

(51) **Int. Cl.**  
**C07C 215/00** (2006.01)  
**A61K 31/00** (2006.01)

(52) **U.S. Cl.**  
USPC ..... **514/357**; 514/649; 514/651; 514/653;  
564/355

(58) **Field of Classification Search**  
None  
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,229,363 A 7/1993 Hammond et al.  
5,284,971 A 2/1994 Walker et al.  
5,447,922 A 9/1995 Lawrence et al.  
5,604,229 A 2/1997 Fujita et al.  
5,830,868 A 11/1998 Bolton et al.  
5,948,820 A 9/1999 Fujita et al.  
6,004,565 A 12/1999 Chiba et al.  
6,214,873 B1 4/2001 Adachi et al.  
6,306,909 B1 10/2001 Weaver et al.  
6,489,331 B1 12/2002 Shimada et al.  
6,960,692 B2 11/2005 Kohno et al.  
6,963,012 B2 11/2005 Kohno et al.  
7,119,138 B1 10/2006 Feeney et al.  
7,179,817 B2 2/2007 Seko et al.  
7,288,558 B2 10/2007 Nakade et al.  
7,456,157 B2 11/2008 Kohno et al.  
7,482,491 B2 1/2009 Kohno et al.  
7,759,326 B2 7/2010 Kohno et al.

7,763,752 B2 7/2010 Kohno et al.  
2002/0040050 A1 4/2002 Xu et al.  
2002/0091105 A1 7/2002 Mandala et al.  
2002/0143034 A1 10/2002 Taniguchi et al.  
2003/0003099 A1 1/2003 Lake et al.  
2003/0018193 A1 1/2003 Ohkubo et al.  
2003/0236297 A1 12/2003 Nishi et al.  
2004/0033995 A1 2/2004 Reid et al.  
2004/0058894 A1 3/2004 Doherty et al.  
2004/0067908 A1 4/2004 Nakade et al.  
2004/0087662 A1 5/2004 Bigaud et al.  
2004/0110728 A1 6/2004 Macdonald et al.  
2004/0138462 A1 7/2004 Sakurai et al.  
2004/0147490 A1 7/2004 Albert et al.  
2004/0224941 A1 11/2004 Seko et al.  
2004/0235794 A1 11/2004 Nakade et al.  
2004/0242654 A1 12/2004 Kohno et al.  
2004/0248952 A1 12/2004 Pan et al.  
2004/0254222 A1 12/2004 Kohno et al.  
2005/0009786 A1 1/2005 Pan et al.  
2005/0020837 A1 1/2005 Doherty et al.  
2005/0033055 A1 2/2005 Bugianesi et al.  
2005/0043386 A1 2/2005 Nishi et al.  
2005/0107345 A1 5/2005 Doherty et al.  
2005/0222422 A1 10/2005 Lynch et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CN 1561331 A 1/2005  
EP 0778263 6/1997

(Continued)

OTHER PUBLICATIONS

Vippagunta et al (Adv Drug Deliv Rev 48:3-26, 2001).\*

(Continued)

*Primary Examiner* — Sreeni Padmanabhan


*Assistant Examiner* — Svetlana M Ivanova

(74) *Attorney, Agent, or Firm* — Wenderoth, Lind & Ponack, L.L.P.

(57) **ABSTRACT**

A novel therapeutic agent or prophylactic agent for an inflammatory bowel disease is provided. An amino alcohol derivative represented by the general formula (1):

[Chemical formula 1]



which is a sphingosine-1-phosphate receptor agonist or a pharmaceutically acceptable salt or hydrate thereof are a therapeutic agent or prophylactic agent for an inflammatory bowel disease comprises.

**4 Claims, No Drawings**

U.S. PATENT DOCUMENTS			WO	94/08943	4/1994	
2005/0245575	A1	11/2005	Chen et al.	WO	96/06068	2/1996
2006/0046979	A1	3/2006	Foster et al.	WO	97/18207	5/1997
2006/0089334	A1	4/2006	Budhu et al.	WO	98/45249	10/1998
2006/0135622	A1*	6/2006	Kohno et al. .... 514/649	WO	00/01388	1/2000
2006/0135786	A1	6/2006	Saha et al.	WO	00/40560	7/2000
2006/0148830	A1	7/2006	Terakado et al.	WO	01/98301	12/2001
2006/0148844	A1	7/2006	Nakade et al.	WO	02/06268	1/2002
2006/0160771	A1	7/2006	Kohno et al.	WO	02/08189	1/2002
2006/0161005	A1	7/2006	Doherty et al.	WO	02/18395	3/2002
2006/0166940	A1	7/2006	Buehlmayer et al.	WO	02/062389	8/2002
2006/0211656	A1	9/2006	Albert et al.	WO	02/064616	8/2002
2006/0211658	A1	9/2006	Hinterding et al.	WO	02/067915	9/2002
2006/0252741	A1	11/2006	Colandrea et al.	WO	02/076995	10/2002
2006/0264403	A1	11/2006	Albert	WO	02/092068	11/2002
2007/0010494	A1	1/2007	Ehrhardt et al.	WO	02/094770	11/2002
2007/0043014	A1	2/2007	Doherty et al.	WO	02/100148	12/2002
2007/0088002	A1	4/2007	Lynch et al.	WO	03/020313	3/2003
2007/0088027	A1	4/2007	Seko et al.	WO	03/029184	4/2003
2007/0135501	A1	6/2007	Hinterding et al.	WO	03/029205	4/2003
2007/0149597	A1	6/2007	Nishi et al.	WO	03/040097	5/2003
2007/0167410	A1	7/2007	Pan et al.	WO	03/051876	6/2003
2007/0167425	A1	7/2007	Nakade et al.	WO	03/061567	7/2003
2007/0191468	A1	8/2007	Nishi et al.	WO	03/062248	7/2003
2007/0203100	A1	8/2007	Pan et al.	WO	03/062252	7/2003
2007/0225260	A1	9/2007	Hinterding et al.	WO	03/073986	9/2003
2008/0025973	A1	1/2008	Fleenor et al.	WO	03/074008	9/2003
2008/0027508	A1	1/2008	Chu	WO	03/105771	12/2003
2008/0032923	A1	2/2008	Kudou et al.	WO	2004/002531	1/2004
2008/0033024	A1	2/2008	Sandanayaka et al.	WO	2004/010949	2/2004
2008/0153882	A1	6/2008	Nishi et al.	WO	2004/024673	3/2004
2008/0161410	A1	7/2008	Kusters et al.	WO	2004/026817	4/2004
2008/0200438	A1	8/2008	Albert et al.	WO	2004/058149	7/2004
2008/0207584	A1	8/2008	Habashita et al.	WO	2004/071442	8/2004
2008/0207941	A1	8/2008	Tsubuki et al.	WO	2004/074297	9/2004
2008/0249093	A1	10/2008	Colandrea et al.	WO	2004/096752	11/2004
2009/0023797	A1	1/2009	Azzaoui et al.	WO	2004/096757	11/2004
2009/0082311	A1	3/2009	Kiuchi et al.	WO	2004/103279	12/2004
2009/0137685	A1	5/2009	Kojima et al.	WO	2004/103306	12/2004
2009/0156653	A1	6/2009	Kohno et al.	WO	2004/103309	12/2004
2009/0253802	A1	10/2009	Kaneko et al.	WO	2004/110979	12/2004
2009/0325907	A1	12/2009	Kohno et al.	WO	2004/113330	12/2004
2010/0010000	A1	1/2010	Kohno et al.	WO	2005/014525	2/2005
2010/0093745	A1	4/2010	Kuriyama et al.	WO	2005/014603	2/2005
				WO	2005/020882	3/2005
				WO	2005/021503	3/2005
				WO	2005/032465	4/2005
EP	1 002 792	5/2000		WO	2005/040091	5/2005
EP	1092435	4/2001		WO	2005/041899	5/2005
EP	1 431 275	6/2004		WO	2005/044780	5/2005
EP	1 431 284	6/2004		WO	2005/058848	6/2005
EP	1602660	12/2005		WO	2005/063671	7/2005
GB	2 400 318	10/2004		WO	2005/070886	8/2005
JP	05-70495	3/1993		WO	2005/079788	9/2005
JP	07-509462	10/1995		WO	2005/082089	9/2005
JP	2579602	11/1996		WO	2005/082841	9/2005
JP	9-504547	5/1997		WO	2005/085179	9/2005
JP	11-080026	3/1999		WO	2005/105146	11/2005
JP	2000-502050	2/2000		WO	2005/118523	12/2005
JP	2000-154151	6/2000		WO	2006/001463	1/2006
JP	2001-515483	9/2001		WO	2006/009092	1/2006
JP	2002-053575	2/2002		WO	2006/011554	2/2006
JP	2002-167382	6/2002		WO	2006/020951	2/2006
JP	2002-316985	10/2002		WO	2006/041015	4/2006
JP	2002-534415	10/2002		WO	2006/041019	4/2006
JP	2003-137894	5/2003		WO	2006/063033	6/2006
JP	2003-523339	8/2003		WO	2006/129688	12/2006
JP	2003-267936	9/2003		WO	2006/137509	12/2006
JP	2004-137208	5/2004		WO	2007/028821	3/2007
JP	2004-307439	11/2004		WO	2007/043433	4/2007
JP	2004-307440	11/2004		WO	2007/043568	4/2007
JP	2004-307441	11/2004		WO	2007/091501	8/2007
JP	2004-307442	11/2004		WO	2007/126042	11/2007
JP	2005-41867	2/2005		WO	2008/018427	2/2008
JP	2005-047899	2/2005		WO	2008/018447	2/2008
JP	2007-169194	7/2007		WO	2008/019306	2/2008
JP	2008-231027	10/2008		WO	2008/099781	8/2008
JP	2008-239546	10/2008		WO		
WO	94/02448	3/1994		WO		



WO	2009/119395	10/2009
WO	2009/142194	11/2009
WO	2009/142195	11/2009

## OTHER PUBLICATIONS

Han (Advances in Characterization of Pharmaceutical Hydrates. Trends in Bio/Pharmaceutical Industry, pp. 25-29. Mar. 2006).\*

International Search Report issued Mar. 3, 2009 in International (PCT) Application No. PCT/JP2009/052037.

Brinkmann et al., The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors, *J. Biol. Chem.*, 2002, vol. 277, No. 24, pp. 21453-21457.

Campbell et al., The Synthesis of Novel Amino Acids via Hydroboration-Suzuki Cross Coupling, *Tetrahedron Letters*, 1999, vol. 40, pp. 5263-5266.

Chisari, Francis V., Cytotoxic T Cells and Viral Hepatitis, *J. Clin. Invest.*, Apr. 1997, vol. 99, No. 7, pp. 1472-1477.

Collier et al., The direct synthesis of novel enantiomerically pure  $\alpha$ -amino acids in protected form via Suzuki cross-coupling, *Tetrahedron Letters*, 2000, vol. 41, pp. 7115-7119.

Ebers, George C., Randomised double-blind placebo-controlled study of interferon  $\beta$ -1a in relapsing/remitting multiple sclerosis, *Lancet*, Nov. 7, 1998, vol. 352, pp. 1498-1501.

Forrest et al., Immune Cell Regulation and Cardiovascular Effects of Sphingosine 1-Phosphate Receptor Agonists in Rodents are Mediated via Distinct Receptor Subtypes, *J. Pharm. Exp. Ther.*, 2004, vol. 309, No. 2, pp. 758-768.

Fried et al., Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection, *N. Engl. J. Med.*, Sep. 26, 2002, vol. 347, No. 13, pp. 975-982.

Ganem et al., The Molecular Biology of the Hepatitis B Virus, *Annu. Rev. Biochem.*, 1987, vol. 56, pp. 651-693.

Gon et al., S1P<sub>3</sub> receptor-induced reorganization of epithelial tight junctions comprises lung barrier integrity and is potentiated by TNF, *PNAS*, Jun. 28, 2005, vol. 102, No. 26, pp. 9270-9275.

Goodin et al., Disease modifying therapies in multiple sclerosis; Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines, *Neurology*, 2002, vol. 58, pp. 169-178.

Hashimoto et al., " $\beta$ -Phenylselenoalanine as a dehydroalanine precursor-efficient synthesis of alternariolide (AM-toxin I)", *Chem. Commun.*, 1996, pp. 1139-1140.

Hinterding et al., Synthesis of Chiral Analogues of FTY720 and its Phosphate, *Synthesis*, 2003, No. 11, pp. 1667-1670.

IFNB Multiple Sclerosis Study Group, Interferon beta-1b is effective in relapsing/remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial, *Neurology*, Apr. 1993, vol. 43, pp. 655-661.

Igarashi, Yasuyuki, Sphingosine-1-Phosphate as an Intercellular Signaling Molecule, *Ann. NY Acad. Sci.*, 1998, vol. 845, pp. 19-31.

Jacobs et al., Intramuscular Interferon Beta-1a for Disease Progression in Relapsing Multiple Sclerosis, *Ann. Neurol.*, 1996, vol. 39, No. 3, pp. 285-294.

Johnson et al., Copolymer 1 reduces relapse rate and improves disability in relapsing/remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial, *Neurology*, Jul. 1995, vol. 45, pp. 1268-1276.

Kaneko et al., Sphingosine-1-phosphate receptor agonists suppress concanavalin A-induced hepatic injury in mice, *Biochem. and Biophys. Res. Commun.*, 2006, vol. 345, pp. 85-92.

Kappos et al., Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis, *N. Engl. J. Med.*, Sep. 14, 2006, vol. 355, No. 11, pp. 1124-1140.

Keller et al., Immunomodulator FTY720 Induces Myofibroblast Differentiation via the Lysophospholipid Receptor S1P<sub>3</sub> and Smad3 Signaling, *Am. J. Pathology*, Jan. 2007, vol. 170, No. 1, pp. 281-292.

Kiuchi et al., Synthesis and Immunosuppressive Activity of 2-Substituted 2-Aminopropane-1,3-diols and 2-Aminoethanols, *J. Med. Chem.*, 2000, vol. 43, pp. 2946-2961.

Klein et al., Total Synthesis and Antifungal Evaluation of Cyclic Aminohexapeptides, *Bioorg. Med. Chem.*, 2000, vol. 8, pp. 1677-1696.

Levkau et al., High-Density Lipoprotein Stimulates Myocardial Perfusion in Vivo, *Circulation*, 2004, vol. 110, pp. 3355-3359.

Long et al., Enantioselective syntheses of homophenylalanine derivatives via nitron 1,3-dipolar cycloaddition reactions with styrenes, *Tetrahedron Letters*, 2001, vol. 42, pp. 5343-5345.

Mailliard et al., Suppressing Hepatitis B without Resistance—So Far, So Good, *N. Engl. J. Med.*, Feb. 27, 2003, vol. 348, No. 9, pp. 848-850.

Mandala et al., Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists, *Science*, Apr. 12, 2002, vol. 296, pp. 346-349.

Niessen et al., Dendritic cell PAR1-S1P3 signalling couples coagulation and inflammation, *Nature*, Apr. 3, 2008, vol. 452, No. 3, pp. 654-658.

Okazaki et al., Molecular Cloning of a Novel Putative G Protein-Coupled Receptor Expressed in the Cardiovascular System, *Biochem. and Biophys. Res. Commun.*, 1993, vol. 190, No. 3, pp. 1104-1106.

Paty et al., Interferon beta-1b is effective in relapsing/remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial, *Neurology*, Apr. 1993, vol. 43, pp. 662-667.

Rudick et al., Management of Multiple Sclerosis, *N. Engl. J. Med.*, Nov. 27, 1997, vol. 337, No. 22, pp. 1604-1611.

Saito et al., Hepatitis C virus infection is associated with the development of hepatocellular carcinoma, *Proc. Natl. Acad. Sci. USA*, Sep. 1990, vol. 87, pp. 6547-6549.

Salomone et al., S1P<sub>3</sub> receptors mediate the potent constriction of cerebral arteries by sphingosine-1-phosphate, *Eur. J. Pharmacol.*, 2003, vol. 469, pp. 125-134.

Sanna et al., Sphingosine 1-Phosphate (S1P) Receptor Subtypes S1P<sub>1</sub> and S1P<sub>3</sub>, Respectively, Regulate Lymphocyte Recirculation and Heart Rate, *J. Biol. Chem.*, Apr. 2, 2004, vol. 279, No. 14, pp. 13839-13848.

Shimizu et al., KRP-203, a Novel Synthetic Immunosuppressant, Prolongs Graft Survival and Attenuates Chronic Rejection in Rat Skin and Heart Allografts, *Circulation*, 2005, vol. 111, pp. 222-229.

Takahashi et al., A Novel Immunomodulator KRP-203 Combined with Cyclosporine Prolonged Graft Survival and Abrogated Transplant Vasculopathy in Rat Heart Allografts, *Transplant. Proc.*, 2005, vol. 37, pp. 143-145.

Takuwa et al., Subtype-specific, differential activities of the EDG family receptors for sphingosine-1-phosphate, a novel lysophospholipid mediator, *Mol. Cell. Endocrinol.*, 2001, vol. 177, pp. 3-11.

Viscido et al., Inflammatory bowel diseases: clinical update of practical guidelines, *Nucl. Med. Commun.*, 2005, vol. 26, No. 7, pp. 649-655.

Weinshenker et al., A Randomized Trial of Plasma Exchange in Acute Central Nervous System Inflammatory Demyelinating Disease, *Ann. Neurol.*, 1999, vol. 46, No. 6, pp. 878-886.

Zivadnov et al., Effects of IV methylprednisolone on brain atrophy in relapsing/remitting MS, *Neurology*, 2001, vol. 57, pp. 1239-1247.

Kohno, Yasushi et al., "Discovery of KRP-203, A potent and orally active new type of immunosuppressant, Sphingosine-1-phosphate receptor agonist", American Chemical Society, National meeting, Washington, D.C., vol. 229, No. Part 2, Mar. 1, 2005, pp. U150, XP008071718.

Daniel, Carolin, et al., "Therapeutic effects of the new lymphocyte homing reagent FTY720 in TNBS-colitis", *Gastroenterology*, vol. 128, No. 4, Suppl. 2, Apr. 2005, pp. A199, XP009128860.

Australian Office Action issued Mar. 7, 2007 in Australian Application No. 2002332289.

Canadian Office Action issued Mar. 9, 2009 in Canadian Application No. 2,461,212.

Chinese Office Action issued Apr. 22, 2005 in Chinese Patent Application No. 02819062.9 (English translation).

Chinese Office Action issued Aug. 25, 2006 in Chinese Patent Application No. 02819062.9 (English translation).

Chinese Office Action issued Nov. 4, 2005 in Chinese Patent Application No. 02819062.9 (English translation).

Indian Office Action issued Apr. 9, 2008 in Indian Application No. 687/DELNP/2004 (English translation).



- Indian Office Action issued Mar. 27, 2009 in Indian Application No. 687/DELNP/2004 (English translation).
- Mexican Office Action dated Apr. 18, 2007 in Mexican Patent Application No. 4002679 (English translation).
- United States Office Action mailed Dec. 21, 2004 in U.S. Appl. No. 10/489,820.
- Supplementary European Search Report mailed Jan. 18, 2006 in Application No. 02768057.8.
- United States Office Action mailed Dec. 21, 2004 in U.S. Appl. No. 10/490,345.
- Supplementary European Search Report mailed Apr. 21, 2006 in Application No. 02768056.
- Australian Office Action dated Oct. 3, 2008 in Australian Application No. 2003264430.
- Chinese Office Action issued Jun. 23, 2006 in Chinese Patent Application No. 03822466.6 (with English translation).
- Letter Regarding Indian Office Action in Indian Patent Application No. 01427/DELNP/2005, dated Dec. 11, 2006.
- Indian Office Action dated Nov. 2, 2006 in Indian Patent Application No. 01427/DELNP/2005 (English translation only).
- Letter Regarding Indian Office Action in Indian Patent Application No. 01427/DELNP/2005 (English translation only), dated Oct. 25, 2007.
- United States Office Action mailed Aug. 24, 2007 in U.S. Appl. No. 10/528,240.
- United States Office Action mailed Feb. 13, 2008 in U.S. Appl. No. 10/528,240.
- Chinese Office Action issued Oct. 27, 2006 in Chinese Patent Application No. 200480004551 (with English translation).
- European Office Action dated May 19, 2008 in European Application No. 04 712 184.3.
- Indian Office Action dated Apr. 2, 2009 in Indian Patent Application 3970/DELNP/2005 (English translation only).
- Letter Regarding Indian Patent Application 3970/DELNP/2005 (English translation only), dated Apr. 30, 2008.
- United States Office Action dated Apr. 21, 2008 in U.S. Appl. No. 10/545,790.
- United States Office Action dated Oct. 29, 2007 in U.S. Appl. No. 10/545,790.
- Supplementary European Search Report dated Feb. 20, 2008 in Patent Application No. 04712184.3.
- Supplementary European Search Report dated Jun. 9, 2009 in Application No. 05766305.
- United States Office Action dated Apr. 14, 2009 in U.S. Appl. No. 11/631,128.
- United States Office Action dated Jun. 27, 2008 in U.S. Appl. No. 11/631,128.
- Blam, Michael E., et al. Integrating Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Current and Future Perspectives, *The American Journal of Gastroenterology*, vol. 96, No. 7 (2001).
- Letter regarding Ecuadorian Application No. SP-08-8662PCT (English translation only), dated Jan. 28, 2009.
- Letter Regarding Ecuadorian Application No. SP-09-9149PCT (English translation only), dated Aug. 17, 2009.
- Letter Regarding Ecuadorian Application No. SP-09-9159PCT (English translation only), dated Aug. 27, 2009.
- Supplementary European Search Report issued Feb. 16, 2010 in European Application No. 07713815.4-2123.
- Deguchi, Yasuyuki et al., "Effects of FTY720 on DSS-induced enteritis in mice", Presented at Area 15, Kobe, International Exhibition Hall Building 1, 2<sup>nd</sup> floor, Oct. 6, 2005, Japanese Society of Gastroenterology (abstract).
- The Merck Manual, Chapter 31: Inflammatory Bowel Diseases, 17<sup>th</sup> edition (1999), pp. 302-307.
- Podolsky, Daniel K., *Inflammatory Bowel Disease*, *N. Engl. J. Med.*, Aug. 8, 2002, vol. 347, No. 6, pp. 417-429.

\* cited by examiner

1

**THERAPEUTIC AGENT OR PROPHYLACTIC  
AGENT FOR INFLAMMATORY BOWEL  
DISEASE COMPRISING AMINO ALCOHOL  
DERIVATIVE AS ACTIVE INGREDIENT**

TECHNICAL FIELD

The present invention relates to a therapeutic agent for inflammatory bowel disease, which comprises an amino alcohol derivative, a pharmacologically acceptable salt thereof or hydrate thereof as an active ingredient, or a method for treating inflammatory bowel disease.

BACKGROUND OF THE INVENTION

Inflammatory bowel disease, wherein Crohn's disease and ulcerative colitis are its main typical diseases, is an intractable disease which occurs at a relatively young generation and causes symptoms such as abdominal pain, fever, diarrhea and melena. Crohn's disease is a idiopathic granulomatous inflammatory disorder in which lesion progresses from ulcer, fibrosis and then to stricture, in discontinuously from mucosa to whole layers of intestinal tract through all digestive tracts from mouth to anus, and is defined as a disorder that shows systemic symptoms such as abdominal pain, chronic diarrhea, fever and malnutrition. Also, ulcerative colitis is an idiopathic diffuse non-specific inflammation of the large intestine, which mainly affects mucosa and frequently forms erosion and ulcer and is a disease which shows various general symptoms including bloody diarrhea. Other inflammatory bowel diseases, namely enteritis occurring in small intestine or large intestine, include intestinal Behcet's disease, hemorrhagic rectal ulcer, pouchitis and the like. Regarding the cause of inflammatory bowel disease, it is considered that an abnormal immune function is concerned, but its exact cause is not known yet (Non-patent Reference 1 and 2).

Immunosuppressants, steroids, salazosulfa-pyridine, mesalazine and the like are used in the medication of inflammatory bowel disease. Regarding the immunosuppressants, it is said that antimetabolites, particularly azathiopurine, 6-mercaptopurine and the like, are effective for Crohn's disease, but these are low in the clinical effect at early stage of administration and frequently show side effects such as allergy, pancreatitis and leukopenia. Cyclosporin at a high dose shows therapeutic effect for inflammatory and fistula diseases, but its long-term use is contraindication because of various toxicities. A monoclonal antibody or infliximab which inhibits tumor necrosis factor is used by intravenous injection for moderate or severe Crohn's disease (particularly accompanied by fistulas) having resistance to other treatments, but its long-term effects and side effects have not been revealed. As the other convincing immune regulation therapy, an interleukin-1 inhibitor, an antibody for interleukin-12, an anti-CD4 antibody, an adherent molecule inhibitor, a down regulatory cytokine or a monoclonal antibody for tumor necrosis factor have been tried. Though there are many such experiential therapeutic approaches, the current drug therapy for inflammatory bowel disease is imperfect. Accordingly, it has been hoped the development of a medicine which is further effective with high safety (Non-patent References 3, 4 and 5).

Non-patent Reference 1: Research and Study Group on Specific Disease Intractable Inflammatory Intestinal Disease, Ministry of Welfare, Research Report in 1997

Non-patent Reference 2: New Engl. J. Med., 2002, 347: 417-429

2

Non-patent Reference 3: Am. J. Gastroenterol., 2001, 96: 1977-1997

Non-patent Reference 4: Nucl. Med. Commun., 2005, 26: 649-655

5 Non-patent Reference 5: Saishin Igaku (Newest Medical Science), 2004, 59: 1070-1075

DISCLOSURE OF THE INVENTION

Problems that the Invention is to Solve

10 An object of the invention is to provide a therapeutic agent for inflammatory bowel disease comprising an amino alcohol derivative as an active ingredient or a method for treating inflammatory bowel disease.


Means for Solving the Problems

20 The present inventors have found that a specific amino alcohol derivative is useful in treating inflammatory bowel diseases (Crohn's disease, ulcerative colitis and the like) and thereby accomplished the invention.

Specifically, the invention relates to:

25 1) a therapeutic agent or prophylactic agent for inflammatory bowel disease, comprising as an active ingredient an amino alcohol derivative or a pharmaceutically acceptable salt or hydrate thereof, wherein the amino alcohol derivative is represented by the general formula (1),


[Chemical formula 1]



40 [wherein R<sup>1</sup> represents a chlorine atom or a straight-chain alkyl group having 1 to 3 carbon atoms or trifluoromethyl group, R<sup>2</sup> represents a fluorine atom or a chlorine atom, R<sup>3</sup> represents a straight-chain alkyl group having 1 to 3 carbon atoms, X represents an oxygen atom or a sulfur atom, and n denotes 2 or 3],

45 2) the therapeutic agent or prophylactic agent for inflammatory bowel disease, comprising as an active ingredient the amino alcohol derivative according to 1), or a pharmaceutically acceptable salt or hydrate thereof, wherein the compound represented by the general formula (1) is a compound represented by the general formula (1a),

55 [Chemical formula 2]



[wherein R<sup>3</sup>, X, and n are as described above],

65 3) the therapeutic agent or prophylactic agent for inflammatory bowel disease, comprising as an active ingredient the amino alcohol derivative according to 1) or 2), or a pharma-



## 3

aceutically acceptable salt or hydrate thereof, wherein in the general formula (1a),  $R^3$  is a methyl group,

4) the therapeutic agent or prophylactic agent for inflammatory bowel disease, comprising as an active ingredient the amino alcohol derivative according to 1), or a pharmaceutically acceptable salt or hydrate thereof, wherein the compound represented by the general formula (1) is,

(R)-2-amino-5-[2-chloro-4-(3-trifluoromethylphenoxy)phenyl]-2-methylpentan-1-ol,

(R)-2-amino-5-[2-chloro-4-(3-trifluoromethylphenylthio)phenyl]-2-methylpentan-1-ol,

(R)-2-amino-4-[2-chloro-4-(3-trifluoromethylphenoxy)phenyl]-2-methylbutan-1-ol,

(R)-2-amino-4-[2-chloro-4-(3-trifluoromethylphenylthio)phenyl]-2-methylbutan-1-ol,


(R)-2-amino-5-[2-chloro-4-(3-ethylphenylthio)phenyl]-2-methylpentan-1-ol,

(R)-2-amino-5-[2-fluoro-4-(3-trifluoromethylphenylthio)phenyl]-2-methylpentan-1-ol, or

(R)-2-amino-5-[2-chloro-4-(3-trifluoromethylphenylthio)phenyl]-2-propylpentan-1-ol,


5) a therapeutic agent or prophylactic agent for inflammatory bowel disease, comprising as an active ingredient an optically active amino alcohol derivative, or a pharmaceutically acceptable salt or hydrate thereof, being obtainable by a step of allowing a compound represented by the general formula (2),

[Chemical formula 3]



[wherein  $R^1$  represents a chlorine atom or a straight-chain alkyl group having 1 to 3 carbon atoms or trifluoromethyl group,  $R^2$  represents a fluorine atom or a chlorine atom, A represents a halogen atom, X represents an oxygen atom or a sulfur atom, and n denotes 2 or 3] and a compound represented by the general formula (10),

[Chemical formula 4]



[wherein  $R^3$  represents a straight-chain alkyl group having 1 to 3 carbon atoms and  $R^4$  represents an alkyl group having 1 to 6 carbon atoms] to act in the presence of a base, and a step of subjecting the resultant product to acidolysis, then further protecting a nitrogen atom with a t-butoxycarbonyl group, reducing, and deprotecting the nitrogen atom], and  
6) a method of treating or preventing inflammatory bowel disease, the method comprising administering the amino alcohol derivative according to any one of 1) to 5), or a pharmaceutically acceptable salt or hydrate thereof

## 4

## ADVANTAGE OF THE INVENTION

According to the invention, it became possible to provide a therapeutic agent or prophylactic agent for inflammatory bowel diseases (Crohn's disease, ulcerative colitis, intestinal Behcet's disease, hemorrhagic rectal ulcer, pouchitis and the like), which shows fewer side effects.

## BEST MODE FOR CARRYING OUT THE INVENTION

In the present invention, the straight-chain alkyl group having 1 to 3 carbon atoms of  $R^1$  and  $R^3$  is a methyl group, an ethyl group, or an n-propyl group.

From the perspective of obtaining high safety,  $R^1$  is preferably an ethyl group, a propyl group, or a trifluoromethyl group, and more preferably is a trifluoromethyl group. Furthermore,  $R^3$  is preferably a methyl group, and n is preferably 3.


Furthermore, the configuration of  $R^3$  is preferably a configuration produced as the principal product via the below-described synthesis route B (using the compound (10)).


In the present invention, examples of pharmaceutically acceptable salts include acid addition salts such as hydrochloride salts, hydrobromic acid salts, acetic acid salts, trifluoroacetic acid salts, methanesulfonic acid salts, citric acid salts, or tartaric acid salts.

The active ingredient of the therapeutic agent or prophylactic agent according to the present invention represented by the general formula (1) can be produced, for example, via the synthesis route A shown below.

## &lt;Synthesis Route A&gt;


[Chemical formula 5]






In the synthesis route A, the compound represented by the general formula (3),

[Chemical formula 6]




[wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $X$  and  $n$  are as described above], can be produced by allowing a compound represented by the general formula (2),

[Chemical formula 7]



[wherein  $R^1$ ,  $R^2$ ,  $A$ ,  $X$ , and  $n$  are as described above], and a compound represented by the general formula (7),


[Chemical formula 8]



[wherein  $R^3$  and  $R^4$  are as described above] to act in the presence of a base (step A-1).

The reaction can be carried out using methanol, ethanol, 1,4-dioxane, dimethylsulfoxide (DMSO), N,N-dimethylformamide (DMF), tetrahydrofuran (THF) or the like as a reaction solvent, in the presence of an inorganic base such as sodium hydride, potassium hydride, sodium methoxide, sodium ethoxide, sodium t-butoxide, potassium methoxide, potassium ethoxide, potassium t-butoxide, or potassium carbonate, at 0° C. to reflux temperature as the reaction temperature, and preferably at 80° C. to 100° C.

In the synthesis route A, the compound represented by the general formula (4),




[wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $X$ , and  $n$  are as described above], can be produced by hydrolyzing the compound represented by the general formula (3) (step A-2).

The reaction can be carried out in the presence of a base such as aqueous sodium hydroxide, aqueous potassium hydroxide, or aqueous lithium hydroxide, using methanol, ethanol, 1,4-dioxane, DMF, DMSO, THF or the like as a reaction solvent, at a reaction temperature of 0° C. to reflux temperature. Preferably, the reaction is carried out using potassium hydroxide as the base, in an ethanol solvent, by reacting at 50° C.

Although the compound according to the present invention is preferably a specific optically-active substance, when the optical resolution is carried out is not especially limited. At this stage, optical resolution may be carried out by HPLC using a chiral column, whereby the desired compound having a chiral center can be obtained.

In the synthesis route A, the compound represented by the general formula (5),

[Chemical formula 10]



[wherein  $R^5$  represents an alkyl group having 1 to 6 carbon atoms, and  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $X$ , and  $n$  are as described above], can be produced by subjecting the compound represented by the general formula (4) to Curtius rearrangement (step A-3).

In the reaction, typical methods for converting a carboxyl group into a carbamate may be employed. For example, a method which combines, for example, chloroethyl carbonate and  $\text{NaN}_3$ , or oxalyl chloride and  $\text{NaN}_3$ , or a method which uses only diphenylphosphoryl azide (DPPA) may be utilized. The reaction is preferably carried out by, after heating diphenylphosphoryl azide to reflux in the presence of an organic base, such as triethylamine, in benzene or toluene solvent, charging the resultant product with an alcohol represented by the general formula (8),



[herein  $R^5$  is as described above], and continuing to heat the resultant solution under stirring, or, after removing the solvent used in the above reaction, such as benzene or toluene, by evaporation, by heating to reflux using the alcohol represented by the general formula (8) as a reaction solvent.


At this stage, optical resolution may be carried out by HPLC using a chiral column, whereby the desired compound having a chiral center can be obtained.

In the synthesis route A, the compound represented by the general formula (6),



7

[Chemical formula 11]



[wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^5$ ,  $X$ , and  $n$  are as described above], can be produced by reducing the compound represented by the general formula (5) (step A-4).

The reaction can be carried out using borane, an alkyl borane derivative like 9-borabicyclo[3.3.1]nonane (9-BBN), or a metal hydride complex compound, such as diisobutylaluminum hydride ( $(iBu)_2AlH$ ), sodium borohydride ( $NaBH_4$ ), lithium borohydride ( $LiBH_4$ ), and lithium aluminum hydride ( $LiAlH_4$ ), preferably  $LiBH_4$ , using THF, 1,4-dioxane, ethanol, or methanol as a reaction solvent, at a temperature of  $0^\circ C$ . to reflux temperature, and preferably at room temperature.


Furthermore, at this stage also, optical resolution may be carried out by HPLC using a chiral column, whereby the desired compound having a chiral center can be obtained.

In the synthesis route A, the compound represented by the general formula (1) can be produced by subjecting the compound represented by the general formula (6) to acidolysis or hydrolysis (step A-5).

The reaction can be carried out at room temperature to reflux temperatures in an inorganic acid or organic acid, such as hydrochloric acid, hydrobromic acid, methanesulfonic acid, acetic acid, and trifluoroacetic acid, or at room temperature to reflux temperature by adding an organic solvent such as methanol, ethanol, THF, or 1,4-dioxane to an inorganic acid or organic acid, such as hydrochloric acid, hydrobromic acid, methanesulfonic acid, acetic acid, and trifluoroacetic acid. The reaction may also be carried out in the presence of a base such as aqueous sodium hydroxide, aqueous potassium hydroxide, and aqueous lithium hydroxide, using methanol, ethanol, THF, 1,4-dioxane, DMSO, or DMF as a reaction solvent, at a temperature of  $0^\circ C$ . to reflux temperature, and preferably  $80$  to  $100^\circ C$ .

In the synthesis route A, among the compounds represented by the general formula (5), compounds in which  $R^5$  represents a t-butyl group, specifically, a compound represented by the general formula (5a),


[Chemical formula 12]



[wherein Boc represents a t-butoxycarbonyl group, and  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $X$ , and  $n$  are as described above], and among the compounds represented by the general formula (6) in the synthesis route A, compounds in which  $R^5$  represents a t-butyl group, specifically, a compound represented by the general formula (6a),

8




[Chemical formula 13]



[wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $X$ , Boc, and  $n$  are as described above], can be produced by the synthesis route B.


&lt;Synthesis Route B&gt;

[Chemical formula 14]



In the synthesis route B, the compound represented by the general formula (9),

[Chemical formula 15]






9

[wherein  $R^1, R^2, R^3, R^4, X,$  and  $n$  are as described above], can be produced by allowing a compound represented by the general formula (2) and a compound represented by the general formula (10),

[Chemical formula 16]



[wherein  $R^3$  and  $R^4$  are as described above] to react in the presence of a base (step B-1).

The reaction can be carried out using a reaction solvent such as 1,4-dioxane, THF, and ether, using a base such as *n*-butyllithium or lithium diisopropyl amide, preferably *n*-butyllithium, and treating a compound represented by the general formula (10) at  $-78^\circ\text{C}$ ., then allowing a compound represented by general formula (2) to react at  $-78^\circ\text{C}$ ., and reacting while gradually increasing the temperature to room temperature.

In the synthesis route B, the compound represented by the general formula (5a) can be produced by subjecting a compound represented by the general formula (9) to acidolysis, and then protecting the nitrogen atom with a *t*-butoxycarbonyl group (Boc group) (step B-2).

In the reaction, an amino ester can be obtained using methanol, ethanol, THF, 1,4-dioxane, or ethyl acetate in which hydrochloric acid is dissolved, and preferably 1,4-dioxane containing hydrochloric acid, by reacting at reflux temperature, then neutralizing with a base. Furthermore, it is preferred to allowing it to react with  $\text{Boc}_2\text{O}$  at  $0^\circ\text{C}$ . to room temperature using ethyl acetate, THF, DMF, 1,4-dioxane, methylene chloride, chloroform, methanol, ethanol, acetonitrile or the like as a solvent.

In the synthesis route B, the compound represented by the general formula (6a) can be produced by reducing a compound represented by the general formula (5a) (step B-3).

The reaction can be carried out using borane, an alkyl borane derivative like 9-BBN, or a metal hydride complex compound, such as  $(i\text{Bu})_2\text{AlH}$ ,  $\text{NaBH}_4$ ,  $\text{LiBH}_4$ , and  $\text{LiAlH}_4$ , preferably  $\text{LiBH}_4$ , using THF, 1,4-dioxane, ethanol, or methanol as a reaction solvent, at a temperature of  $0^\circ\text{C}$ . to reflux temperature, and preferably at room temperature.

It is noted that concerning the synthesis method of the compound represented by the general formula (2), the compound may be produced by the methods described in the respective pamphlets of WO 03029184, WO 03029205, WO 04026817, WO 04074297, and WO 050444780.

The therapeutic agent or prophylactic agent for inflammatory bowel diseases, which comprises the compound obtained in this manner as an active ingredient, is systemically or topically administered orally or parenterally. Dosage form of the compound can be changed in response to the properties of the compound, and it is possible to be prepared as an oral preparation or a parenteral preparation. That is, granules, powders, tablets, capsules, syrups, suppositories, suspensions, solutions and the like can be prepared by mixing the active ingredient with physiologically acceptable carriers, fillers, binders, diluents and the like.

10

The inflammatory bowel disease according to the invention means enteritis which occurs in small intestine or large intestine, and Crohn's disease, ulcerative colitis, intestinal Behcet's disease, hemorrhagic rectal ulcer, pouchitis and the like can be exemplified.

As the clinical dose, though it changes depending on the body weight, age and the condition to be treated, it is generally from 0.01 to 100 mg, preferably from 0.1 to 5 mg, per one person as the amount per once, and from 1 to 3 times per day is convenient.

## EXAMPLES


The present invention will be described with the following specific examples. However, the present invention is not limited by these examples.

Furthermore, as the intermediates and the like represented by the general formula (2), the compounds in the pamphlets of WO 03029184, WO 03029205, WO 04026817, WO 04074297, and WO 050444780 may be utilized. Furthermore, (5*S*)-3,6-diethoxy-5-isopropyl-2-methyl-2,5-dihydropyrazine, (5*S*)-3,6-dimethoxy-5-isopropyl-2-methyl-2,5-dihydropyrazine, and (5*S*)-2-allyl-3,6-diethoxy-5-isopropyl-2,5-dihydropyrazine were synthesized according to Ulrich Shollkopf et. al, *Synthesis* 969 (1981) and Chunrong Ma et. al., *J. Org. Chem.*, 66, 4525 (2001). Intermediates and the like which were newly synthesized based on the experiment procedures described in these reference documents will now be described as the following reference examples.

## Reference Example 1

## 2-Fluoro-4-(3-trifluoromethylphenylthio)benzaldehyde

[Chemical formula 17]



Under an argon atmosphere, ethyldiisopropylamine (7.0 mL), tris(dibenzylideneacetone)dipalladium(0) chloroform adduct (518 mg), xantphos (578 mg), and 3-trifluoromethylthiophenol (3.56 g) were added at room temperature into a solution of 4-bromo-2-fluorobenzaldehyde (4.06 g) in 1,4-dioxane (42 mL), and the resultant solution was heated to reflux for 5 hours. To the reaction solution added water, extracted with ethyl acetate, washed with water and saturated brine in that order, and then dried over anhydrous sodium sulfate. The solvent was evaporated, and the resultant residue was purified by silica gel column chromatography (hexane: ethyl acetate=30:1) to obtain the target product (4.08 g) as a colorless oil.

$^1\text{H-NMR}$  ( $\text{CDCl}_3$ , 400 MHz):  $\delta$  6.86 (1H, dd,  $J=10, 1.8$  Hz), 7.02 (1H, dd,  $J=7.9, 1.8$  Hz), 7.58 (1H, t,  $J=7.9$  Hz), 7.68-7.73 (2H, m), 7.76 (1H, t,  $J=7.9$  Hz), 7.80 (1H, s), 10.26 (1H, s)

EIMS (+): 300  $[\text{M}]^+$ .




## 11

## Reference Example 2

## 2-Chloro-4-(3-chlorophenylthio)benzaldehyde

[Chemical formula 18]



3-Chlorobenzenethiol and 2-chloro-4-fluorobenzaldehyde were reacted according to the same experiment procedures as in Reference Example 1 of the pamphlet of WO 03029205 to obtain the target product as a colorless oil.


$^1\text{H-NMR}$  ( $\text{CDCl}_3$ , 400 MHz):  $\delta$  7.11 (1H, dd,  $J=9.2$ , 1.8 Hz), 7.17 (1H, d,  $J=1.8$  Hz), 7.36-7.44 (3H, m), 7.52 (1H, t,  $J=1.8$  Hz), 7.80 (1H, d,  $J=7.9$  Hz), 10.37 (1H, s)

EIMS (+): 282  $[\text{M}]^+$ .

## Reference Example 3

## 2-Chloro-4-(3-methylphenoxy)benzaldehyde

[Chemical formula 19]



m-Cresol and 2-chloro-4-fluorobenzaldehyde were reacted according to the same experiment procedures as in Reference Example 1 of the pamphlet of WO 03029184 to obtain the target product as a colorless powder.


$^1\text{H-NMR}$  ( $\text{CDCl}_3$ , 400 MHz):  $\delta$  2.38 (3H, s), 6.87-6.96 (4H, m), 7.07 (1H, d,  $J=7.3$  Hz), 7.31 (1H, t,  $J=7.6$  Hz), 7.90 (1H, d,  $J=8.6$  Hz), 10.36 (1H, s).

EIMS (+): 246  $[\text{M}]^+$ .

## Reference Example 4

## 2-Chloro-4-(3-ethylphenylthio)benzaldehyde

[Chemical formula 20]



3-Ethylbenzenethiol and 2-chloro-4-fluorobenzaldehyde were reacted according to the same experiment procedures as in Reference Example 1 of the pamphlet of WO 03029205 to obtain the target product as a colorless oil.

$^1\text{H-NMR}$  ( $\text{CDCl}_3$ , 400 MHz):  $\delta$  1.26 (3H, t,  $J=7.3$  Hz), 2.68 (2H, q,  $J=7.3$  Hz), 7.04-7.11 (2H, m), 7.28-7.40 (4H, m), 7.76 (1H, d,  $J=8.6$  Hz), 10.35 (1H, s).


EIMS (+): 276  $[\text{M}]^+$ .

## 12

## Reference Example 5

## 2-Chloro-4-(3-propylphenoxy)benzaldehyde

[Chemical formula 21]



3-Propylphenol and 2-chloro-4-fluorobenzaldehyde were reacted according to the same experiment procedures as in Reference Example 1 of the pamphlet of WO 03029184 to obtain the target product as a pale brown oil.


$^1\text{H-NMR}$  ( $\text{CDCl}_3$ , 400 MHz):  $\delta$  0.95 (3H, t,  $J=7.3$  Hz), 1.62-1.68 (2H, m), 2.61 (2H, t,  $J=7.3$  Hz), 6.89-6.94 (3H, m), 6.96 (1H, d,  $J=2.1$  Hz), 7.08 (1H, d,  $J=7.9$  Hz), 7.31-7.35 (1H, m), 7.90 (1H, d,  $J=8.9$  Hz), 10.36 (1H, d,  $J=0.6$  Hz).

EIMS (+): 274  $[\text{M}]^+$ .

## Reference Example 6

## [2-Chloro-4-(3-ethylphenylthio)phenyl]acetaldehyde

[Chemical formula 22]




The compound of Reference Example 4 was reacted according to the same experiment procedures as in Reference Example 326 of the pamphlet of WO 04074297 to obtain the target product as a pale yellow oil.

## Reference Example 7

Ethyl  
3-[2-chloro-4-(3-ethylphenylthio)phenyl]acrylate

[Chemical formula 23]



The compound of Reference Example 4 was reacted according to the same experiment procedures as in Reference Example 10 of the pamphlet of WO 03029205 to obtain the target product as a pale yellow oil.


EIMS (+): 346  $[\text{M}]^+$ .



## 13

## Reference Example 8

3-[2-Chloro-4-(3-ethylphenylthio)phenyl]propan-1-ol




The compound of Reference Example 7 was reacted according to the same experiment procedures as in Reference Example 19 of the pamphlet of WO 03029205, and the resultant product was then reduced according to the same experiment procedures as in Reference Example 35 of the pamphlet of WO 03029205, to obtain the target product as a colorless oil.

$^1\text{H-NMR}$  ( $\text{CDCl}_3$ , 400 MHz):  $\delta$  1.22 (3H, t,  $J=7.3$  Hz), 1.84-1.90 (2H, m), 2.62 (2H, q,  $J=7.6$  Hz), 2.78-2.82 (2H, m), 3.69 (2H, t,  $J=6.1$  Hz), 7.10-7.18 (4H, m), 7.23-7.29 (3H, m).

## Reference Example 9

3-[2-Chloro-4-(3-propylphenoxy)phenyl]propan-1-ol




The compound of Reference Example 5 was successively reacted according to the same procedures as in Reference Example 7 and then Reference Example 8 to obtain the target product as a colorless oil.

$^1\text{H-NMR}$  ( $\text{CDCl}_3$ , 400 MHz):  $\delta$  0.94 (3H, t,  $J=7.3$  Hz), 1.37 (1H, br s), 1.58-1.68 (2H, m), 1.85-1.92 (2H, m), 2.57 (2H, t,  $J=7.6$  Hz), 2.80 (2H, t,  $J=7.6$  Hz), 3.70 (2H, dt,  $J=6.1$ , 4.6 Hz), 6.80-6.85 (3H, m), 6.95 (1H, d,  $J=7.9$  Hz), 7.00 (1H, d,  $J=2.8$  Hz), 7.17 (1H, d,  $J=8.3$  Hz), 7.24 (1H, t,  $J=7.9$  Hz).  
EIMS (+): 304  $[\text{M}]^+$ .

## Reference Example 10

3-[2-Fluoro-4-(3-trifluoromethylphenylthio)phenyl]propan-1-ol




The compound of Reference Example 1 was successively reacted according to the same procedures as in Reference Example 7 and then Reference Example 8 to obtain the target product as a colorless oil.

## 14

$^1\text{H-NMR}$  ( $\text{CDCl}_3$ , 400 MHz):  $\delta$  1.88 (2H, tt,  $J=6.7$ , 6.1 Hz), 2.75 (2H, t,  $J=6.7$  Hz), 3.69 (2H, t,  $J=6.1$  Hz), 7.05 (1H, dd,  $J=10$ , 1.8 Hz), 7.10 (1H, dd,  $J=7.9$ , 1.8 Hz), 7.20 (1H, t,  $J=7.9$  Hz), 7.38-7.51 (3H, m), 7.55 (1H, s).

## Reference Example 11

3-[2-Chloro-4-(3-chlorophenylthio)phenyl]propan-1-ol




The compound of Reference Example 2 was successively reacted according to the same procedures as in Reference Example 7 and then Reference Example 8 to obtain the target product as a colorless oil.

$^1\text{H-NMR}$  ( $\text{CDCl}_3$ , 400 MHz):  $\delta$  1.33 (1H, br s), 1.83-1.95 (2H, m), 2.81-2.85 (2H, m), 3.70 (2H, br s), 7.15-7.23 (5H, m), 7.24-7.29 (1H, m), 7.38 (1H, d,  $J=1.8$  Hz).

## Reference Example 12

3-[2-Chloro-4-(3-methylphenoxy)phenyl]propan-1-ol




The compound of Reference Example 3 was successively reacted according to the same procedures as in Reference Example 7 and then Reference Example 8 to obtain the target product as a colorless oil.

$^1\text{H-NMR}$  ( $\text{CDCl}_3$ , 400 MHz):  $\delta$  1.31 (1H, brs), 1.87-1.90 (2H, m), 2.34 (3H, s), 2.80 (2H, t,  $J=7.3$  Hz), 3.70 (2H, dd,  $J=11.6$ , 6.1 Hz), 6.79-6.86 (3H, m), 6.94 (1H, d,  $J=7.3$  Hz), 6.99 (1H, d,  $J=2.4$  Hz), 7.18 (1H, d,  $J=7.9$  Hz), 7.22 (1H, t,  $J=7.3$  Hz).

EIMS (+): 276  $[\text{M}]^+$ .

## Reference Example 13

2-Chloro-4-(3-ethylphenylthio)-1-(2-iodoethyl)benzene



The compound of Reference Example 6 was reacted according to the same experiment procedures as in Reference



## 15


Example 327 of the pamphlet of WO 04074297 to obtain the target product as a colorless oil.

$^1\text{H-NMR}$  ( $\text{CDCl}_3$ , 400 MHz):  $\delta$  1.22 (3H, t,  $J=7.3$  Hz), 2.63 (2H, q,  $J=7.3$  Hz), 3.23-3.28 (2H, m), 3.32-3.35 (2H, m), 7.09-7.29 (7H, m).

EIMS (+): 402  $[\text{M}]^+$ .

## Reference Example 14

## 2-Chloro-4-(3-ethylphenylthio)-1-(3-iodopropyl) benzene




The compound of Reference Example 8 was reacted according to the same experiment procedures as in Reference Example 164 of the pamphlet of WO 03029184 to obtain the target product as a colorless oil.

$^1\text{H-NMR}$  ( $\text{CDCl}_3$ , 400 MHz):  $\delta$  1.22 (3H, t,  $J=7.3$  Hz), 2.12 (2H, quintet,  $J=7.3$  Hz), 2.63 (2H, q,  $J=7.3$  Hz), 2.81 (2H, t,  $J=7.3$  Hz), 3.19 (2H, t,  $J=7.3$  Hz), 7.09-7.19 (4H, m), 7.24-7.28 (3H, m).

EIMS (+): 416  $[\text{M}]^+$ .

## Reference Example 15

## 2-Chloro-1-(3-iodopropyl)-4-(3-propylphenoxy) benzene



The compound of Reference Example 9 was reacted according to the same experiment procedures as in Reference Example 164 of the pamphlet of WO 03029184 to obtain the target product as a pale yellow oil.

$^1\text{H-NMR}$  ( $\text{CDCl}_3$ , 400 MHz):  $\delta$  0.94 (3H, t,  $J=7.3$  Hz), 1.60-1.68 (2H, m), 2.10-2.17 (2H, m), 2.57 (2H, t,  $J=7.6$  Hz), 2.81 (2H, t,  $J=7.6$  Hz), 3.21 (2H, t,  $J=7.0$  Hz), 6.80-6.85 (3H, m), 6.96 (1H, d,  $J=7.9$  Hz), 6.99 (1H, d,  $J=2.4$  Hz), 7.19 (1H, d,  $J=8.3$  Hz), 7.25 (1H, t,  $J=7.9$  Hz).


EIMS (+): 414  $[\text{M}]$

## 16

## Reference Example 16

## 2-Fluoro-1-(3-iodopropyl)-4-(3-(trifluoromethylphenylthio)benzene

[Chemical formula 32]



The compound of Reference Example 10 was reacted according to the same experiment procedures as in Reference Example 164 of the pamphlet of WO 03029184 to obtain the target product as a colorless oil.


$^1\text{H-NMR}$  ( $\text{CDCl}_3$ , 400 MHz):  $\delta$  2.13 (2H, quintet,  $J=7.3$  Hz), 2.76 (2H, t,  $J=7.3$  Hz), 3.18 (2H, t,  $J=6.7$  Hz), 7.03 (1H, dd,  $J=10$ , 1.8 Hz), 7.09 (1H, dd,  $J=7.9$ , 1.8 Hz), 7.20 (1H, t,  $J=7.9$  Hz), 7.39-7.52 (3H, m), 7.57 (1H, s).

EIMS (+): 404  $[\text{M}]^+$ .

## Reference Example 17

## 2-Chloro-4-(3-chlorophenylthio)-1-(3-iodopropyl) benzene

[Chemical formula 33]



The compound of Reference Example 11 was reacted according to the same experiment procedures as in Reference Example 164 of the pamphlet of WO 03029184 to obtain the target product as a colorless oil.


$^1\text{H-NMR}$  ( $\text{CDCl}_3$ , 400 MHz):  $\delta$  2.14 (2H, tt,  $J=7.3$ , 6.7 Hz), 2.84 (2H, t,  $J=7.3$  Hz), 3.20 (2H, t,  $J=6.7$  Hz), 7.16-7.25 (5H, m), 7.28 (1H, t,  $J=1.8$  Hz), 7.36 (1H, d,  $J=1.8$  Hz).

EIMS (+): 422  $[\text{M}]^+$ .

## Reference Example 18

## 2-Chloro-1-(3-iodopropyl)-4-(3-methylphenoxy) benzene

[Chemical formula 34]



The compound of Reference Example 12 was reacted according to the same experiment procedures as in Reference Example 164 of the pamphlet of WO 03029184 to obtain the target product as a yellow oil.

$^1\text{H-NMR}$  ( $\text{CDCl}_3$ , 400 MHz):  $\delta$  2.13 (2H, quint,  $J=7.3$  Hz), 2.34 (3H, s), 2.81 (2H, t,  $J=7.3$  Hz), 3.21 (2H, t,  $J=7.3$  Hz),



## 17


6.81-6.84 (3H, m), 6.95 (1H, d, J=7.9 Hz), 6.99 (1H, d, J=2.4 Hz), 7.18 (1H, d, J=7.9 Hz), 7.23 (1H, t, J=7.9 Hz).

EIMS (+): 386 [M]<sup>+</sup>.

## Example 1

(2R,5S)-2-[2-chloro-4-(3-trifluoromethylphenoxy)phenyl]propyl-3,6-diethoxy-5-isopropyl-2-methyl-2,5-dihydropyrazine

[Chemical formula 35]




Under an argon atmosphere, a solution of n-butyllithium in hexane (1.54 mol/L, 3.59 mL) was added at -78° C. into a solution of (5S)-3,6-diethoxy-5-isopropyl-2-methyl-2,5-dihydropyrazine (905 mg) in THF (16 mL), and the resultant solution was stirred at -78° C. for 30 minutes. Next, a solution of 2-chloro-1-(3-iodopropyl)-4-(3-trifluoromethylphenoxy)benzene (2.47 g) in THF (4 mL) was added to the reaction mixture, and the resultant solution was stirred at -78° C. for 30 minutes and then at 0° C. for 1 hour. To the reaction solution was added water, extracted with ethyl acetate, washed with water and saturated brine in that order, and then dried over anhydrous sodium sulfate. The solvent was evaporated, and the resultant residue was purified by silica gel column chromatography (hexane:ethyl acetate=60:1) to obtain the target product (1.59 g) as a colorless oil.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>, 400 MHz): δ 0.70 (3H, d, J=6.7 Hz), 1.05 (3H, d, J=6.7 Hz), 1.18-1.50 (9H, m), 1.32 (3H, s), 1.86-1.97 (1H, m), 2.21-2.30 (1H, m), 2.65 (2H, t, J=7.6 Hz), 3.90 (1H, d, J=2.1 Hz), 3.97-4.21 (4H, m), 6.84 (1H, dd, J=7.9, 2.4 Hz), 7.00 (1H, d, J=2.4 Hz), 7.15 (2H, d, J=7.9 Hz), 7.24 (1H, br s), 7.36 (1H, d, J=7.9 Hz), 7.44 (1H, t, J=7.9 Hz).

## Example 2

(2R,5S)-2-[2-chloro-4-(3-trifluoromethylphenylthio)phenyl]propyl-3,6-diethoxy-5-isopropyl-2-methyl-2,5-dihydropyrazine

[Chemical formula 36]



(5S)-3,6-diethoxy-5-isopropyl-2-methyl-2,5-dihydropyrazine and 2-chloro-1-(3-iodopropyl)-4-(3-trifluoromethylphenylthio)benzene were reacted in the same manner as in Example 1 to obtain the target product as a colorless oil.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>, 400 MHz): δ 0.63 (3H, d, J=6.7 Hz), 1.07 (3H, d, J=6.7 Hz), 1.18-1.29 (10H, m), 1.34-1.66 (2H, m), 1.79-1.91 (1H, m), 2.25-2.33 (1H, m), 2.70 (2H, t, J=7.6


## 18

Hz), 3.85 (1H, br s), 3.99-4.23 (4H, m), 7.16 (2H, d, J=7.9 Hz), 7.20 (1H, dd, J=7.9, 1.8 Hz), 7.36-7.42 (3H, m), 7.44-7.50 (1H, m), 7.52 (1H, br s).

## Example 3

(2R,5S)-2-[2-chloro-4-(3-trifluoromethylphenoxy)phenyl]ethyl-3,6-diethoxy-5-isopropyl-2-methyl-2,5-dihydropyrazine

[Chemical formula 37]



(5S)-3,6-diethoxy-5-isopropyl-2-methyl-2,5-dihydropyrazine and 2-chloro-1-(2-iodoethyl)-4-(3-trifluoromethylphenoxy)benzene were reacted in the same manner as in Example 1 to obtain the target product as a colorless oil.


<sup>1</sup>H-NMR (CDCl<sub>3</sub>, 400 MHz): δ 0.72 (3H, d, J=6.7 Hz), 1.08 (3H, d, J=6.7 Hz), 1.29 (6H, t, J=7.3 Hz), 1.36 (3H, s), 1.74-1.82 (1H, m), 2.13-2.20 (1H, m), 2.25-2.32 (1H, m), 2.39-2.56 (2H, m), 3.95 (1H, d, J=3.1 Hz), 4.02-4.22 (4H, m), 6.83 (1H, dd, J=8.6, 2.4 Hz), 6.99 (1H, d, J=2.4 Hz), 7.12-7.15 (2H, m), 7.23 (1H, br s), 7.35 (1H, d, J=7.8 Hz), 7.44 (1H, t, J=7.8 Hz).

EIMS (+): 524 [M]<sup>+</sup>.

## Example 4

(2R,5S)-2-[2-chloro-4-(3-trifluoromethylphenylthio)phenyl]ethyl-3,6-diethoxy-5-isopropyl-2-methyl-2,5-dihydropyrazine

[Chemical formula 38]



(5S)-3,6-diethoxy-5-isopropyl-2-methyl-2,5-dihydropyrazine and 2-chloro-1-(2-iodoethyl)-4-(3-trifluoromethylphenylthio)benzene were reacted in the same manner as in Example 1 to obtain the target product as a colorless oil.


<sup>1</sup>H-NMR (CDCl<sub>3</sub>, 400 MHz): δ 0.72 (3H, d, J=6.7 Hz), 1.08 (3H, d, J=6.7 Hz), 1.28 (6H, t, J=7.3 Hz), 1.35 (3H, s), 1.68-1.90 (1H, m), 2.10-2.19 (1H, m), 2.38-2.57 (1H, m), 3.95 (1H, d, J=3.1 Hz), 4.02-4.22 (4H, m), 7.13 (1H, d, J=7.9 Hz), 7.18 (1H, dd, J=7.9, 2.4 Hz), 7.35-7.42 (3H, m), 7.43-7.48 (1H, m), 7.54 (1H, br s).



## 19

## Example 5

(2R,5S)-2-[2-chloro-4-(3-ethylphenylthio)phenyl]ethyl-3,6-diethoxy-5-isopropyl-2-methyl-2,5-dihydropyrazine




(5S)-3,6-diethoxy-5-isopropyl-2-methyl-2,5-dihydropyrazine and the compound of Reference Example 13 were reacted in the same manner as in Example 1 to obtain the target product as a colorless oil.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>, 400 MHz): δ 0.72 (3H, d, J=6.7 Hz), 1.07 (3H, d, J=6.7 Hz), 1.21 (3H, t, J=7.3 Hz), 1.28 (3H, t, J=7.3 Hz), 1.29 (3H, t, J=7.3 Hz), 1.34 (3H, s), 1.70-1.79 (1H, m), 2.09-2.16 (1H, m), 2.24-2.32 (1H, m), 2.35-2.52 (2H, m), 2.61 (2H, q, J=7.3 Hz), 3.95 (1H, d, J=3.1 Hz), 4.03-4.20 (4H, m), 7.04-7.15 (4H, m), 7.21-7.26 (3H, m).

ESIMS (+): 501 [M+H]<sup>+</sup>.

## Example 6

(2R,5S)-2-[2-chloro-4-(3-methylphenoxy)phenyl]propyl-3,6-dimethoxy-5-isopropyl-2-methyl-2,5-dihydropyrazine



(5S)-3,6-dimethoxy-5-isopropyl-2-methyl-2,5-dihydropyrazine and the compound of Reference Example 18 were reacted in the same manner as in Example 1 to obtain the target product as a colorless oil.


<sup>1</sup>H-NMR (CDCl<sub>3</sub>, 400 MHz): δ 0.68 (3H, d, J=6.7 Hz), 1.07 (3H, d, J=6.7 Hz), 1.33 (3H, s), 1.36-1.43 (1H, m), 1.55-1.62 (1H, m), 1.86-1.92 (1H, m), 2.24-2.26 (1H, m), 2.34 (3H, s), 2.62 (2H, t, J=7.9 Hz), 3.65 (3H, s), 3.66 (3H, s), 3.94 (1H, d, J=3.7 Hz), 6.79-6.82 (3H, m), 6.93 (1H, d, J=7.3 Hz), 6.96 (1H, d, J=2.4 Hz), 7.09 (1H, d, J=7.9 Hz), 7.22 (1H, t, J=7.9 Hz).

EIMS (+): 456 [M]<sup>+</sup>.

## 20

## Example 7

(2R,5S)-2-[2-chloro-4-(3-ethylphenylthio)phenyl]propyl-3,6-diethoxy-5-isopropyl-2-methyl-2,5-dihydropyrazine




(5S)-3,6-diethoxy-5-isopropyl-2-methyl-2,5-dihydropyrazine and the compound of Reference Example 14 were reacted in the same manner as in Example 1 to obtain the target product as a colorless oil.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>, 400 MHz): δ 0.68 (3H, d, J=6.7 Hz), 1.04 (3H, d, J=6.7 Hz), 1.20-1.26 (9H, m), 1.31 (3H, s), 1.36-1.43 (1H, m), 1.50-1.57 (1H, m), 1.85-1.92 (1H, m), 2.21-2.28 (1H, m), 2.60-2.65 (4H, m), 3.88 (1H, d, J=3.7 Hz), 4.00-4.16 (4H, m), 7.06-7.16 (4H, m), 7.22-7.27 (3H, m).

ESIMS (+): 515 [M+H]<sup>+</sup>.

## Example 8

(2R,5S)-2-[2-chloro-4-(3-chlorophenylthio)phenyl]propyl-3,6-diethoxy-5-isopropyl-2-methyl-2,5-dihydropyrazine



(5S)-3,6-diethoxy-5-isopropyl-2-methyl-2,5-dihydropyrazine and the compound of Reference Example 17 were reacted in the same manner as in Example 1 to obtain the target product as a colorless oil.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>, 400 MHz): δ 0.69 (3H, d, J=6.7 Hz), 1.08 (3H, d, J=6.7 Hz), 1.18-1.29 (7H, m), 1.31 (3H, s), 1.34-1.47 (1H, m), 1.50-1.63 (1H, m), 1.85-1.95 (1H, m), 2.20-2.30 (1H, m), 2.65 (2H, t, J=7.6 Hz), 3.89 (1H, d, J=3.1 Hz), 3.99-4.23 (4H, m), 7.11-7.23 (6H, m), 7.35 (1H, d, J=1.8 Hz).


ESIMS (+): 521 [M+H]<sup>+</sup>.



## 21

## Example 9

(2R,5S)-2-[2-fluoro-4-(3-trifluoromethylphenylthio)phenyl]propyl-3,6-diethoxy-5-isopropyl-2-methyl-2,5-dihydropyrazine




(5S)-3,6-diethoxy-5-isopropyl-2-methyl-2,5-dihydropyrazine and the compound of Reference Example 16 were reacted in the same manner as in Example 1 to obtain the target product as a colorless oil.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>, 400 MHz): δ 0.67 (3H, d, J=6.7 Hz), 1.06 (3H, d, J=6.7 Hz), 1.18-1.29 (7H, m), 1.33 (3H, s), 1.36-1.66 (2H, m), 1.85-1.95 (1H, m), 2.23-2.33 (1H, m), 2.67 (2H, t, J=7.6 Hz), 3.89 (1H, d, J=3.1 Hz), 3.99-4.23 (4H, m), 7.02 (1H, dd, J=9.8 Hz, 1.8 Hz), 7.08 (1H, dd, J=7.9 Hz, 2.4 Hz), 7.13 (1H, t, J=7.9 Hz), 7.38-7.50 (3H, m), 7.55 (1H, s).

## Example 10

(2S,5S)-2-allyl-2-[2-chloro-4-(3-trifluoromethylphenylthio)phenyl]propyl-3,6-diethoxy-5-isopropyl-2,5-dihydropyrazine



(5S)-2-allyl-3,6-diethoxy-5-isopropyl-2,5-dihydropyrazine and 2-chloro-1-(3-iodopropyl)-4-(3-trifluoromethylphenylthio)benzene were reacted in the same manner as in Example 1 to obtain the target product as a colorless oil.


<sup>1</sup>H-NMR (CDCl<sub>3</sub>, 400 MHz): δ 0.67 (3H, d, J=6.7 Hz), 1.05 (3H, d, J=6.7 Hz), 1.23 (3H, t, J=6.4 Hz), 1.25 (3H, t, J=6.4 Hz), 1.30-1.64 (3H, m), 1.80-1.90 (1H, m), 2.23-2.39 (2H, m), 2.53 (1H, dd, J=12.4, 7.3 Hz), 2.65 (2H, t, J=7.6 Hz), 3.83 (1H, d, J=3.1 Hz), 4.03-4.18 (4H, m), 4.92-5.04 (2H, m), 5.60-5.73 (1H, m), 7.13 (2H, d, J=7.9 Hz), 7.18 (1H, dd, J=7.9 Hz, 1.8 Hz), 7.36 (1H, d, J=1.8 Hz), 7.38-7.42 (2H, m), 7.44-7.49 (1H, m), 7.55 (1H, br s).

## 22

## Example 11

Ethyl(R)-2-*t*-butoxycarbonylamino-5-[2-chloro-4-(3-trifluoromethylphenoxy)phenyl]-2-methylpentanoate

[Chemical formula 45]




To a solution of the compound of Example 1 (1.59 g) in 1,4-dioxane (60 mL) was added 0.5 mol/L hydrochloric acid (30 mL). The resultant solution was stirred at room temperature for 1 hour, and then left to stand at room temperature overnight. The solution was concentrated, neutralized with saturated aqueous sodium hydrogen carbonate solution, and extracted with ethyl acetate. The extract was washed with water and saturated brine, and then dried over anhydrous sodium sulfate. The extract was concentrated, and the resultant residue was dissolved in acetonitrile (15 mL). To this solution was added di-*tert*-butoxydicarbonate (1.55 g), and the resultant solution was stirred at room temperature for 4 hours and then left to stand at room temperature overnight. To the reaction solution added water, extracted with ethyl acetate, washed with water and saturated brine in that order, and then dried over anhydrous sodium sulfate. The solvent was evaporated, and the resultant residue was purified by silica gel column chromatography (hexane:ethyl acetate=9:1) to obtain the target product (1.00 g) as a colorless oil.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>, 400 MHz): δ 1.26 (3H, t, J=7.3 Hz), 1.43 (9H, s), 1.53 (3H, s), 1.45-1.68 (2H, m), 1.80-1.90 (1H, m), 2.12-2.30 (1H, m), 2.69 (2H, t, J=7.6 Hz), 4.16-4.24 (2H, m), 5.33 (1H, br s), 6.85 (1H, dd, J=7.9 Hz, 2.4 Hz), 7.02 (1H, d, J=2.4 Hz), 7.15 (1H, dd, J=7.9 Hz, 2.4 Hz), 7.17 (1H, d, J=7.9 Hz), 7.24 (1H, br s), 7.37 (1H, d, J=7.9 Hz), 7.45 (1H, t, J=7.9 Hz).

## Example 12

Ethyl(R)-2-*t*-butoxycarbonylamino-5-[2-fluoro-4-(3-trifluoromethylphenylthio)phenyl]-2-methylpentanoate

[Chemical formula 46]




The compound of Example 9 was reacted in the same manner as in Example 11 to obtain the target product as a colorless oil.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>, 400 MHz): δ 1.26 (3H, t, J=7.3 Hz), 1.42 (9H, s), 1.51 (3H, s), 1.45-1.68 (2H, m), 1.77-1.86 (1H, m), 2.09-2.20 (1H, m), 2.69 (2H, t, J=7.6 Hz), 4.13-4.23 (2H, m), 5.29 (1H, br s), 7.02 (1H, dd, J=9.8 Hz, 1.8 Hz), 7.08 (1H, dd, J=7.9 Hz, 2.4 Hz), 7.13 (1H, t, J=7.9 Hz), 7.38-7.50 (3H, m), 7.55 (1H, s).

## 23

## Example 13

Ethyl(S)-2-allyl-2-t-butoxycarbonylamino-5-[2-chloro-4-(3-trifluoromethylphenylthio)phenyl]pentanoate




The compound of Example 10 was reacted in the same manner as in Example 11 to obtain the target product as a colorless oil.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>, 400 MHz) δ 1.24 (3H, t, J=7.3 Hz), 1.29-1.39 (1H, m), 1.43 (9H, s), 1.60-1.70 (1H, m), 1.78-1.86 (1H, m), 2.32-2.50 (2H, m), 2.66-2.73 (2H, m), 2.99-3.10 (1H, m), 4.19 (2H, q), 5.03 (1H, d, J=3.1 Hz), 5.09 (1H, s), 5.49 (1H, br s), 5.54-5.68 (1H, m), 7.16 (1H, d, J=7.9 Hz), 7.19 (1H, dd, J=7.9, 1.8 Hz), 7.35 (1H, d, J=1.8 Hz), 7.39-7.44 (2H, m), 7.45-7.50 (1H, m), 7.54 (1H, br s).

## Example 14

Ethyl(R)-2-t-butoxycarbonylamino-5-[2-chloro-4-(3-trifluoromethylphenylthio)phenyl]-2-propylpentanoate



To a solution of the compound of Example 13 (400 mg) in ethyl acetate (20 mL) was added palladium, on activated carbon/ethylene diamine complex (100 mg), and the resultant solution was stirred at room temperature for 24 hours under hydrogen atmosphere. The reaction solution was filtered through Celite, and the solvent was evaporated. The resultant residue was purified by silica gel column chromatography (hexane:ethyl acetate=30:1) to obtain the target product (293 mg) as a colorless oil.


<sup>1</sup>H-NMR (CDCl<sub>3</sub>, 400 MHz): δ 0.91 (3H, t, J=7.3 Hz), 1.42 (9H, s), 1.15-1.77 (8H, m), 2.72 (2H, t, J=7.3 Hz), 3.63 (1H, d, J=12 Hz), 3.67 (1H, d, J=12 Hz), 4.52 (1H, br s), 7.19-7.22 (2H, m), 7.39 (1H, s), 7.40-7.50 (3H, m), 7.54 (1H, br s).

FABMS (+): 532 [M+H]<sup>+</sup>.

## 24

## Example 15

(R)-2-t-butoxycarbonylamino-5-[2-chloro-4-(3-trifluoromethylphenoxy)phenyl]-2-methylpentan-1-ol




To a solution of the compound of Example 11 (1.00 g) in THF (14 mL) was added under ice cooling lithium borohydride (229 mg), and then ethanol (1.4 mL) was added dropwise. The resultant solution was then stirred for 1 hour under ice cooling. To the reaction solution was added 10% aqueous citric acid, extracted with ethyl acetate, washed with water and saturated brine in that order, and then dried over anhydrous sodium sulfate. The solvent was evaporated, and the resultant residue was purified by silica gel column chromatography (hexane:ethyl acetate=4:1) to obtain the target product (910 mg) as a colorless oil.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>, 400 MHz): δ 1.16 (3H, s), 1.43 (9H, s), 1.53-1.74 (3H, m), 1.81-1.93 (1H, m), 2.73 (2H, t, J=7.3 Hz), 3.61 (1H, d, J=12 Hz), 3.65 (1H, d, J=12 Hz), 4.58 (1H, br s), 4.58 (1H, br s), 6.86 (1H, dd, J=7.9, 2.4 Hz), 7.03 (1H, d, J=2.4 Hz), 7.16 (1H, dd, J=7.9 Hz, 2.4 Hz), 7.21 (1H, d, J=7.9 Hz), 7.24 (1H, br s), 7.37 (1H, d, J=7.9 Hz), 7.45 (1H, t, J=7.9 Hz).

## Example 16

(R)-2-t-butoxycarbonylamino-5-[2-chloro-4-(3-trifluoromethylphenylthio)phenyl]-2-methylpentan-1-ol



The compound of Example 2 was reacted in the same manner as in Example 11 to obtain an ester, which was then reacted in the same manner as in Example 15 to obtain the target product as a colorless oil.


<sup>1</sup>H-NMR (CDCl<sub>3</sub>, 400 MHz): δ 1.14 (3H, s), 1.42 (9H, s), 1.48-1.76 (4H, m), 1.81-1.90 (1H, m), 2.74 (2H, t, J=6.7 Hz), 3.61 (1H, d, J=12 Hz), 3.65 (1H, d, J=12 Hz), 4.56 (1H, br s), 4.58 (1H, br s), 7.20 (2H, d, J=1.2 Hz), 7.37-7.50 (4H, m), 7.54 (1H, br s). Optical Rotation: [α]<sub>D</sub><sup>27</sup>+14.31 (c 0.63, CHCl<sub>3</sub>).



## 25

## Example 17

(R)-2-t-butoxycarbonylamino-4-[2-chloro-4-(3-trifluoromethylphenoxy)phenyl]-2-methylbutan-1-ol




The compound of Example 3 was reacted in the same manner as in Example 11 to obtain an ester, which was then reacted in the same manner as in Example 15 to obtain the target product as a colorless oil.

$^1\text{H-NMR}$  ( $\text{CDCl}_3$ , 400 MHz):  $\delta$  1.26 (3H, s), 1.45 (9H, s), 1.80-1.88 (1H, m), 2.05-2.12 (1H, m), 2.66-2.80 (2H, m), 3.68 (1H, d,  $J=11.6$  Hz), 3.73 (1H, d,  $J=11.6$  Hz), 4.70 (1H, br s), 6.86 (1H, dd,  $J=8.5, 2.5$  Hz), 7.03 (1H, d,  $J=2.5$  Hz), 7.13-7.16 (1H, m), 7.22-7.24 (2H, m), 7.37 (1H, d,  $J=7.9$  Hz), 7.45 (1H, t,  $J=7.9$  Hz).

FABMS (+): 474  $[\text{M}+\text{H}]^+$ .

## Example 18

(R)-2-t-butoxycarbonylamino-4-[2-chloro-4-(3-trifluoromethylphenylthio)phenyl]-2-methylbutan-1-ol




The compound of Example 4 was reacted in the same manner as in Example 11 to obtain an ester, which was then reacted in the same manner as in Example 15 to obtain the target product as a colorless oil.

$^1\text{H-NMR}$  ( $\text{CDCl}_3$ , 400 MHz):  $\delta$  1.25 (3H, s), 1.44 (9H, s), 1.79-1.89 (1H, m), 2.05-2.13 (1H, m), 2.66-2.83 (2H, m), 3.68 (1H, d,  $J=12$  Hz), 3.71 (1H, d,  $J=12$  Hz), 4.69 (1H, br s), 7.20-7.23 (2H, m), 7.37-7.42 (3H, m), 7.45-7.50 (2H, m), 7.55 (1H, br s).

## 26

## Example 19

(R)-2-t-butoxycarbonylamino-4-[2-chloro-4-(3-ethylphenylthio)phenyl]-2-methylbutan-1-ol




The compound of Example 5 was reacted in the same manner as in Example 11 to obtain an ester, which was then reacted in the same manner as in Example 15 to obtain the target product as a colorless oil.

$^1\text{H-NMR}$  ( $\text{CDCl}_3$ , 400 MHz):  $\delta$  1.22 (3H, t,  $J=7.3$  Hz), 1.24 (3H, s), 1.44 (9H, s), 1.77-1.85 (1H, m), 2.02-2.09 (1H, m), 2.62 (2H, q,  $J=7.3$  Hz), 2.63-2.78 (2H, m), 3.64-3.73 (2H, m), 4.08 (1H, br), 4.68 (1H, br s), 7.10-7.17 (4H, m), 7.22-7.28 (3H, m).

ESIMS (+): 450  $[\text{M}+\text{H}]^+$ .

## Example 20

(R)-2-t-butoxycarbonylamino-5-[2-chloro-4-(3-methylphenoxy)phenyl]-2-methylpentan-1-ol




The compound of Example 6 was reacted in the same manner as in Example 11 to obtain an ester, which was then reacted in the same manner as in Example 15 to obtain the target product as a colorless oil.

$^1\text{H-NMR}$  ( $\text{CDCl}_3$ , 400 MHz):  $\delta$  1.15 (3H, s), 1.43 (9H, s), 1.61-1.67 (3H, m), 1.83-1.87 (1H, m), 2.34 (3H, s), 2.70 (2H, t,  $J=7.0$  Hz), 3.62-3.65 (2H, m), 4.57 (1H, s), 6.81-6.84 (3H, m), 6.94 (1H, d,  $J=7.3$  Hz), 6.98 (1H, d,  $J=3.1$  Hz), 7.15 (1H, d,  $J=7.9$  Hz), 7.22 (1H, t,  $J=7.9$  Hz).

ESIMS (+): 434  $[\text{M}+\text{H}]^+$ .

## Example 21

(R)-2-t-butoxycarbonylamino-5-[2-chloro-4-(3-ethylphenylthio)phenyl]-2-methylpentan-1-ol



## 27


The compound of Example 7 was reacted in the same manner as in Example 11 to obtain an ester, which was then reacted in the same manner as in Example 15 to obtain the target product as a colorless oil.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>, 400 MHz): δ 1.14 (3H, s), 1.22 (3H, t, J=7.3 Hz), 1.43 (9H, s), 1.54-1.70 (3H, m), 1.79-1.89 (1H, m), 2.62 (2H, q, J=7.3 Hz), 2.70 (2H, t, J=7.0 Hz), 3.57-3.66 (2H, m), 4.05 (1H, br), 4.55 (1H, br s), 7.10-7.17 (4H, m), 7.17-7.28 (3H, m).

ESIMS (+): 464 [M+H]<sup>+</sup>.

## Example 22

(R)-2-t-butoxycarbonylamino-5-[2-chloro-4-(3-propylphenoxy)phenyl]-2-methylpentan-1-ol




The compound of Reference Example 15 and (5S)-3,6-diethoxy-5-isopropyl-2-methyl-2,5-dihydropyrazine were reacted with in the same manner as in Example 1. The resultant compound was reacted in the same manner as in Example 11 to obtain an ester, which was then reacted in the same manner as in Example 15 to obtain the target product as a colorless oil.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>, 400 MHz): δ 0.94 (3H, t, J=7.3 Hz), 1.15 (3H, s), 1.24-1.28 (2H, m), 1.43 (9H, s), 1.60-1.69 (3H, m), 1.80-1.90 (1H, m), 2.57 (2H, t, J=7.6 Hz), 2.70 (2H, t, J=7.6 Hz), 3.58-3.67 (2H, m), 4.11 (1H, br s), 4.58 (1H, br s), 6.79-6.85 (3H, m), 6.95 (1H, d, J=7.9 Hz), 6.99 (1H, d, J=2.8 Hz), 7.15 (1H, d, J=8.3 Hz), 7.24 (1H, t, J=7.9 Hz).

## Example 23

(R)-2-t-butoxycarbonylamino-5-[2-chloro-4-(3-chlorophenylthio)phenyl]-2-methylpentan-1-ol



The compound of Example 8 was reacted in the same manner as in Example 11 to obtain an ester, which was then reacted in the same manner as in Example 15 to obtain the target product as a colorless oil.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>, 400 MHz): δ 1.14 (3H, s), 1.43 (9H, s), 1.58-1.74 (3H, m), 1.79-1.92 (1H, m), 2.73 (2H, t, J=6.7 Hz), 3.61 (1H, d, J=12 Hz), 3.64 (1H, d, J=12 Hz), 4.08 (1H, br s), 4.57 (1H, br s), 7.17-7.27 (6H, m), 7.37 (1H, s).


ESIMS (+): 470 [M+H]

## 28

## Example 24

(R)-2-t-butoxycarbonylamino-5-[2-fluoro-4-(3-trifluoromethylphenylthio)phenyl]-2-methylpentan-1-ol

[Chemical formula 58]




The compound of Example 12 was reacted in the same manner as in Example 15 to obtain the target product as a colorless oil.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>, 400 MHz): δ 1.14 (3H, s), 1.42 (9H, s), 1.55-1.74 (3H, m), 1.75-1.85 (1H, m), 2.65 (2H, t, J=6.7 Hz), 3.58-3.64 (2H, m), 4.03 (1H, br s), 4.55 (1H, br s), 7.04 (1H, dd, J=9.8 Hz, 1.8 Hz), 7.10 (1H, dd, J=7.9 Hz, 1.8 Hz), 7.17 (1H, t, J=7.9 Hz), 7.38-7.50 (3H, m), 7.54 (1H, br s).

## Example 25

(R)-2-t-butoxycarbonylamino-5-[2-chloro-4-(3-trifluoromethylphenylthio)phenyl]-2-propylpentan-1-ol

[Chemical formula 59]



The compound of Example 14 was reacted in the same manner as in Example 15 to obtain the target product as a colorless oil.


<sup>1</sup>H-NMR (CDCl<sub>3</sub>, 400 MHz): δ 0.92 (3H, t, J=7.3 Hz), 1.42 (9H, s), 1.14-1.80 (8H, m), 2.72 (2H, t, J=7.3 Hz), 3.62 (1H, d, J=12 Hz), 3.66 (1H, d, J=12 Hz), 4.54 (1H, br s), 7.16-7.22 (2H, m), 7.39 (1H, s), 7.40-7.48 (3H, m), 7.55 (1H, br s).

FABMS (+): 532 [M+H]<sup>+</sup>.

## Example 26

(R)-2-amino-5-[2-chloro-4-(3-trifluoromethylphenoxy)phenyl]-2-methylpentan-1-ol hydrochloride

[Chemical formula 60]



To the compound of Example 15 (6.50 g) was added a 10 w/w % hydrogen chloride solution in methanol (methanol containing hydrogen chloride, 67 mL), and the resultant mix-



## 29

ture was stirred for 1 hour at room temperature, and then left overnight at room temperature. The solvent was then evaporated to obtain the target product (5.15 g) as a colorless amorphous.


<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 400 MHz): δ 1.07 (3H, s), 1.46-1.64 (4H, m), 2.62-2.72 (2H, m), 3.31-3.36 (2H, m), 7.03 (1H, dd, J=7.9, 2.4 Hz), 7.20 (1H, d, J=2.4 Hz), 7.30 (1H, d, J=7.9 Hz), 7.34 (1H, s), 7.39 (1H, d, J=7.9 Hz), 7.52 (1H, d, J=7.9 Hz), 7.63 (1H, t, J=7.9 Hz).

HREIMS (+): 388.1281 (Calcd. for C<sub>19</sub>H<sub>21</sub>NCIF<sub>3</sub>O<sub>2</sub>: 388.1291).

Optical Rotation: [α]<sub>D</sub><sup>23</sup> -2.74 (c 0.63, CHCl<sub>3</sub>).

## Example 27

(R)-2-amino-5-[2-chloro-4-(3-trifluoromethylphenylthio)phenyl]-2-methylpentan-1-ol hydrochloride



The compound of Example 16 was reacted in the same manner as in Example 26 to obtain the target product as a white powder.

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 400 MHz): δ 1.09 (3H, s), 1.49-1.63 (4H, m), 2.65-2.71 (2H, br s), 3.34 (1H, d, J=12 Hz), 3.38 (1H, d, J=12 Hz), 7.34 (1H, dd, J=7.9 Hz, 2.4 Hz), 7.41 (1H, d, J=7.9 Hz), 7.49 (1H, d, J=2.4 Hz), 7.55 (1H, d, J=7.9 Hz), 7.61 (1H, d, J=2.4 Hz), 7.67 (1H, d, J=7.9 Hz), 7.53-7.74 (3H, br s).


ESIMS (+): 404 [M+H]<sup>+</sup>.

Elemental Analysis Measured: C, 51.65%; H, 4.86%; N, 2.86%. Calcd. for C<sub>19</sub>H<sub>22</sub>ClF<sub>3</sub>NOS.HCl: C, 51.82%; H, 5.04%; N, 3.18%.

Optical Rotation: [α]<sub>D</sub><sup>23</sup> -3.45 (c 1.00, CHCl<sub>3</sub>).

## Example 28

(R)-2-amino-4-[2-chloro-4-(3-trifluoromethoxyphenoxy)phenyl]-2-methylbutan-1-ol hydrochloride



The compound of Example 17 was reacted in the same manner as in Example 26 to obtain the target product as a white powder.

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 400 MHz): δ 1.24 (3H, s), 1.70-1.80 (2H, m), 2.71 (2H, t, J=8.6 Hz), 3.44 (1H, dd, J=11 Hz, 4.9 Hz), 3.50 (1H, dd, J=11 Hz, 4.9 Hz), 5.54 (1H, t, J=4.9 Hz), 7.04 (1H, dd, J=8.6, 2.4 Hz), 7.21 (1H, d, J=2.4 Hz), 7.31 (1H,

## 30


dd, J=8.6, 2.4 Hz), 7.35 (1H, br s), 7.41 (1H, d, J=8.6 Hz), 7.52 (1H, d, J=7.9 Hz), 7.63 (1H, t, J=7.9 Hz), 7.95 (3H, br s).

FABMS (+): 374 [M+H]<sup>+</sup>.

Elemental Analysis Measured: C, 52.38%; H, 4.80%; N, 3.42%. Calcd. for C<sub>18</sub>H<sub>19</sub>ClF<sub>3</sub>NO<sub>2</sub>.HCl: C, 52.70%; H, 4.91%; N, 3.41%.

## Example 29

(R)-2-amino-4-[2-chloro-4-(3-trifluoromethylphenylthio)phenyl]-2-methylbutan-1-ol hydrochloride



The compound of Example 18 was reacted in the same manner as in Example 26 to obtain the target product as a white powder.

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 400 MHz): δ 1.22 (3H, s), 1.66-1.83 (2H, m), 2.72 (2H, t, J=8.6 Hz), 3.42 (1H, dd, J=11.0, 7.9 Hz), 3.49 (1H, dd, J=11.0, 7.9 Hz), 5.54 (1H, t, J=4.9 Hz), 7.36 (1H, dd, J=7.9, 1.8 Hz), 7.42 (1H, d, J=7.9 Hz), 7.50 (1H, d, J=1.8 Hz), 7.53-7.64 (3H, m), 7.67 (1H, d, J=7.9 Hz), 7.82 (3H, br s).


FABMS (+): 390 [M+H]<sup>+</sup>.

Elemental Analysis: Measured: C, 50.47%; H, 4.65%; N, 3.36%. Calcd. for C<sub>18</sub>H<sub>19</sub>ClF<sub>3</sub>NOS.HCl: C, 50.71%; H, 4.73%; N, 3.29%.

Optical Rotation: [α]<sub>D</sub><sup>27</sup> +5.78 (c 0.33, CHCl<sub>3</sub>).

## Example 30

(R)-2-amino-4-[2-chloro-4-(3-ethylphenylthio)phenyl]-2-methylbutan-1-ol hydrochloride



The compound of Example 19 was reacted in the same manner as in Example 26 to obtain the target product as a white powder.

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 400 MHz): δ 1.14 (3H, t, J=7.3 Hz), 1.22 (3H, s), 1.67-1.81 (2H, m), 2.59 (2H, q, J=7.3 Hz), 2.69 (2H, t, J=8.6 Hz), 3.42 (1H, dd, J=11.6, 5.5 Hz), 3.48 (1H, dd, J=11.6, 5.5 Hz), 5.52 (1H, t, J=4.9 Hz), 7.16-7.22 (2H, m), 7.26-7.27 (2H, m), 7.30-7.35 (2H, m), 7.93 (3H, br s).


ESIMS (+): 350 [M+H]<sup>+</sup>.

Elemental Analysis Measured: C, 58.90%; H, 6.42%; N, 3.59%. Calcd. for C<sub>19</sub>H<sub>24</sub>ClNOS.HCl: C, 59.06%; H, 6.52%; N, 3.63%.

## 31

## Example 31

(R)-2-amino-5-[2-chloro-4-(3-methylphenoxy)phenyl]-2-methylpentan-1-ol hydrochloride



The compound of Example 20 was reacted in the same manner as in Example 26 to obtain the target product as a colorless amorphous.


<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 400 MHz): δ 1.11 (3H, s), 1.57 (4H, brs), 2.29 (3H, s), 2.64 (2H, brs), 3.35-3.39 (2H, m), 5.45 (1H, t, J=4.9 Hz), 6.81 (1H, dd, J=8.6, 2.4 Hz), 6.85 (1H, s), 6.92 (1H, dd, J=8.6, 2.4 Hz), 6.99 (1H, d, J=8.6 Hz), 7.03 (1H, d, J=2.4 Hz), 7.28 (1H, t, J=8.6 Hz), 7.34 (1H, d, J=8.6 Hz), 7.77 (3H, brs).

HRESIMS (+): 334.15655 (Calcd. for C<sub>19</sub>H<sub>25</sub>ClNO<sub>2</sub>: 334.15738).

Optical Rotation: [α]<sub>D</sub><sup>26.3</sup>-5.75 (c 0.60, CHCl<sub>3</sub>).

## Example 32

(R)-2-amino-5-[2-chloro-4-(3-ethylphenylthio)phenyl]-2-methylpentan-1-ol hydrochloride



The compound of Example 21 was reacted in the same manner as in Example 26 to obtain the target product as a colorless oil.


<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 400 MHz): δ 1.10 (3H, s), 1.15 (3H, t, J=7.3 Hz), 1.52-1.58 (4H, m), 2.59 (2H, q, J=7.3 Hz), 2.62-2.66 (2H, m), 3.32-3.39 (2H, m), 5.43 (br), 7.15-7.22 (3H, m), 7.26 (2H, d, J=1.8 Hz), 7.32 (2H, dd, J=7.3, 1.8 Hz), 7.81 (3H, br s).

HRESIMS (+): 364.15051 (Calcd. for C<sub>20</sub>H<sub>27</sub>ClNOS: 364.15019).

## 32

## Example 33

(R)-2-amino-5-[2-chloro-4-(3-propylphenoxy)phenyl]-2-methylpentan-1-ol hydrochloride



The compound of Example 22 was reacted in the same manner as in Example 26 to obtain the target product as a colorless amorphous.

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 400 MHz): δ 0.86 (3H, t, J=7.3 Hz), 1.11 (3H, s), 1.51-1.61 (6H, m), 2.53 (2H, t, J=7.3 Hz), 2.63 (2H, t, J=6.7 Hz), 3.34-3.42 (2H, m), 5.45 (1H, t, J=4.9 Hz), 6.81 (1H, ddd, J=7.9, 1.8, 0.9 Hz), 6.87 (1H, t, J=1.8 Hz), 6.91 (1H, dd, J=8.6, 2.4 Hz), 7.00 (1H, d, J=7.9 Hz), 7.02 (1H, d, J=2.4 Hz), 7.30 (1H, t, J=7.9 Hz), 7.34 (1H, d, J=8.6 Hz), 7.85 (3H, br s).


ESIMS (+): 362 [M+H]<sup>+</sup>.

HRESIMS (+): 362.19198 (Calcd. for C<sub>21</sub>H<sub>29</sub>ClNO<sub>2</sub>: 362.18868).

Optical Rotation: [α]<sub>D</sub><sup>25.1</sup>-4.46 (c 1.27, CHCl<sub>3</sub>).

## Example 34

(R)-2-amino-5-[2-chloro-4-(3-chlorophenylthio)phenyl]-2-methylpentan-1-ol hydrochloride



The compound of Example 23 was reacted in the same manner as in Example 26 to obtain the target product as a colorless amorphous.

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 400 MHz): δ 1.10 (3H, s), 1.49-1.64 (4H, m), 2.68 (2H, br s), 3.33 (1H, dd, J=12, 4.9 Hz), 3.38 (1H, dd, J=12, 4.9 Hz), 5.45 (1H, t, J=4.9 Hz), 7.26 (1H, dt, J=7.3, 1.8 Hz), 7.30-7.43 (5H, m), 7.45 (1H, d, J=1.8 Hz), 7.77 (3H, br s).

HREIMS (+): 370.0799 (Calcd. for C<sub>18</sub>H<sub>21</sub>Cl<sub>2</sub>NOS: 370.0799).


Optical Rotation: [α]<sub>D</sub><sup>27</sup>-3.81 (c 0.50, CHCl<sub>3</sub>).



## 33

## Example 35

(R)-2-amino-5-[2-fluoro-4-(3-trifluoromethylphenylthio)phenyl]-2-methylpentan-1-ol hydrochloride



The compound of Example 24 was reacted in the same manner as in Example 26 to obtain the target product as a colorless amorphous.


<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 400 MHz): δ 1.09 (3H, s), 1.48-1.61 (4H, m), 2.57-2.64 (2H, br s), 3.32 (1H, dd, J=11, 4.9 Hz), 3.37 (1H, dd, J=11, 4.9 Hz), 5.44 (1H, t, J=4.9 Hz), 7.20 (1H, dd, J=7.9, 1.8 Hz), 7.26 (1H, dd, J=9.8, 1.8 Hz), 7.37 (1H, t, J=7.9 Hz), 7.54-7.68 (4H, m), 7.74 (3H, br s).

HRESIMS (+): 388.1345 (Calcd. for C<sub>19</sub>H<sub>22</sub>F<sub>4</sub>NOS: 388.1358).

Optical Rotation: [α]<sub>D</sub><sup>24</sup> -3.23 (c 0.69, CHCl<sub>3</sub>).

## Example 36

(R)-2-amino-5-[2-chloro-4-(3-trifluoromethylphenylthio)phenyl]-2-propylpentan-1-ol hydrochloride



The compound of Example 25 was reacted in the same manner as in Example 26 to obtain the target product as a white powder.

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 400 MHz): δ 0.84 (3H, t, J=7.3 Hz), 1.20 (2H, q, J=7.3 Hz), 1.36-1.63 (6H, m), 2.68 (2H, t, J=7.3 Hz), 3.36 (2H, d, J=4.9 Hz), 5.40 (1H, d, J=4.9 Hz), 7.35 (1H, dd, J=7.9 Hz, 1.8 Hz), 7.42 (1H, d, J=7.9 Hz), 7.50 (1H, d, J=1.8 Hz), 7.55 (1H, d, J=7.9 Hz), 7.58-7.63 (2H, m), 7.67 (1H, d, J=7.9 Hz), 7.69 (3H, br s).

FABMS (+): 432 [M+H]<sup>+</sup>.


Elemental Analysis Measured: C, 53.46%; H, 5.62%; N, 2.98%. Calcd. for C<sub>21</sub>H<sub>25</sub>ClF<sub>3</sub>NOS.HCl: C, 53.85%; H, 5.59%; N, 2.99%.

Optical Rotation: [α]<sub>D</sub><sup>23</sup> +3.85 (c 0.63, CHCl<sub>3</sub>).

## 34

## Example 37

(R)-2-amino-5-[2-chloro-4-(3-trifluoromethylphenylthio)phenyl]-2-methylpentan-1-ol



To a solution of the compound of Example 27 (9.3 g) in ethyl acetate (450 mL) was added saturated aqueous sodium hydrogen carbonate solution (450 mL), and the resultant solution was stirred at room temperature for 10 minutes. The organic layer was washed with water and saturated brine in that order, and then dried over anhydrous sodium sulfate. The solvent was evaporated, and the resultant residue was purified by NH-silica gel column chromatography (ethyl acetate: methanol=4:1) to obtain the target product (8.9 g) as a white powder.


<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 400 MHz): δ 0.85 (3H, s), 1.21 (2H, br s), 1.28 (2H, t, J=8.6 Hz), 1.46-1.67 (2H, m), 2.65 (2H, t, J=8.6 Hz), 3.06 (2H, br s), 4.49 (1H, br s), 7.32 (1H, dd, J=7.9, 1.8 Hz), 7.40 (1H, d, J=9.8 Hz), 7.47 (1H, d, J=1.8 Hz), 7.54 (1H, dd, J=6.7, 1.8 Hz), 7.56-7.62 (2H, m), 7.65 (1H, dd, J=6.7, 1.8 Hz).

ESIMS (+): 404 [M+H]<sup>+</sup>.

Elemental Analysis Measured: C, 56.26%; H, 5.14%; N, 3.40%. Calcd. for C<sub>19</sub>H<sub>21</sub>ClF<sub>3</sub>NOS: C, 56.50%; H, 5.24%; N, 3.47%.

## Example 38

Diethyl 2-{3-[2-chloro-4-(3-trifluoromethylphenylthio)phenyl]propyl}-2-methylmalonate



2-Chloro-1-(3-iodopropyl)-4-(3-trifluoromethylphenylthio)benzene and diethyl 2-methylmalonate were reacted according to the same procedures as in Example 152 of WO 04026817 to obtain the target product as a colorless oil.


<sup>1</sup>H-NMR (CDCl<sub>3</sub>, 400 MHz): δ 1.25 (6H, t, J=7.4 Hz), 1.40 (3H, s), 1.51-1.63 (2H, m), 1.90-1.97 (2H, m), 2.73 (2H, t, J=7.9 Hz), 4.17 (4H, q, J=7.4 Hz), 7.17-7.23 (2H, m), 7.38 (1H, d, J=2.2 Hz), 7.39-7.44 (2H, m), 7.45-7.50 (1H, m), 7.55 (1H, s).

EIMS (+): 502 [M]<sup>+</sup>.

## 35

## Example 39

(±)-5-[2-chloro-4-(3-trifluoromethylphenylthio)phenyl]-2-ethoxycarbonyl-2-methylpentanoic acid




To a solution of the compound of Example 38 (16.8 g) in ethanol (167 mL) was added potassium hydroxide (2.40 g), and the resultant solution was stirred at 50° C. for 24 hours. To the reaction solution was added water, neutralized with 2 mol/L aqueous hydrochloric acid, and extracted with ethyl acetate. The organic layer was washed with water and saturated brine in that order, and then dried over anhydrous sodium sulfate. The solvent was evaporated, and the resultant residue was purified by silica gel column chromatography (hexane:ethyl acetate=1:1) to obtain the target product (11.2 g) as a colorless oil.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>, 400 MHz): δ 1.26 (3H, t, J=7.4 Hz), 1.47 (3H, s), 1.55-1.66 (2H, m), 1.87-2.06 (2H, m), 2.73 (2H, t, J=7.9 Hz), 4.22 (2H, q, J=7.4 Hz), 7.18 (1H, d, J=7.9 Hz), 7.20 (1H, dd, J=7.9, 1.8 Hz), 7.38 (1H, d, J=1.8 Hz), 7.39-7.44 (2H, m), 7.45-7.50 (1H, m), 7.54 (1H, s).

ESIMS (+): 475 [M+H]<sup>+</sup>.

## Example 40

Ethyl(±)-5-[2-chloro-4-(3-trifluoromethylphenylthio)phenyl]-2-methoxycarbonylamino-2-methylpentanoate



To a solution of the compound of Example 39 (15.8 g) in benzene (166 mL) was added diphenylphosphoryl azide (7.86 mL) and triethylamine (6.01 mL), and the resultant solution was heated to reflux for 1.5 hours. The temperature of the reaction solution was returned to room temperature, and methanol (20 mL) was added dropwise over 20 minutes. The resultant solution was heated to reflux for 30 minutes, and then further sodium methoxide (3.58 g) was added. The resultant solution was heated to reflux for 1.5 hours. To the reaction solution was added saturated aqueous ammonium chloride, and extracted with ethyl acetate. The organic layer was washed with water and saturated brine in that order, and then dried over anhydrous sodium sulfate. The solvent was evaporated, and the resultant residue was purified by silica gel column chromatography (hexane:ethyl acetate=5:1) to obtain the target product (15.6 g) as a colorless oil.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>, 400 MHz): δ 1.25 (3H, t, J=7.3 Hz), 1.32-1.47 (1H, m), 1.52-1.67 (1H, m), 1.57 (3H, s), 1.80-1.90


## 36

(1H, m), 2.20-2.37 (1H, m), 2.62-2.76 (2H, m), 3.64 (3H, s), 4.15-4.25 (2H, m), 5.62 (1H, br s), 7.16 (1H, d, J=7.9 Hz), 7.20 (1H, dd, J=7.9, 1.8 Hz), 7.38 (1H, d, J=1.8 Hz), 7.40-7.44 (2H, m), 7.45-7.50 (1H, m), 7.55 (1H, s).

ESIMS (+): 504 [M+H]<sup>+</sup>.

## Example 41

(±)-5-[2-chloro-4-(3-trifluoromethylphenylthio)phenyl]-2-methoxycarbonyl amino-2-methylpentan-1-ol




To a solution of the compound of Example 40 (15.6 g) in THF (249 mL) was added under ice cooling lithium borohydride (3.75 g), and then ethanol (16.6 mL) was added dropwise. The resultant solution was then stirred for 1 hour under ice cooling. To the reaction solution was added 10% aqueous citric acid, extracted with ethyl acetate, washed with water and saturated brine in that order, and then dried over anhydrous sodium sulfate. The solvent was evaporated, and the resultant residue was purified by silica gel column chromatography (hexane:ethyl acetate=1:1) to obtain the target product (12.9 g) as a colorless oil.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>, 400 MHz): δ 1.18 (3H, s), 1.54-1.74 (3H, m), 1.78-1.89 (1H, m), 2.73 (2H, t, J=7.9 Hz), 3.63 (3H, s), 3.56-3.70 (2H, m), 4.23 (1H, br s), 7.17-7.22 (2H, m), 7.38-7.50 (4H, m), 7.54 (1H, s).

ESIMS (+): 462 [M+H]<sup>+</sup>.

## Example 42

(±)-2-t-butoxycarbonylamino-5-[2-chloro-4-(3-trifluoromethylphenylthio)phenyl]-2-methylpentan-1-ol



To a solution of the compound of Example 41 (12.9 g) in THF (60 mL) and methanol (120 mL) was added under ice cooling 5 mol/L aqueous potassium hydroxide solution (60 mL), and the resultant solution was heated to reflux for 86 hours. To the reaction solution was added water, extracted with ethyl acetate, washed with water and saturated brine in that order, and then dried over anhydrous sodium sulfate. The extract was concentrated, the residue was dissolved in 1,4-dioxane (279 mL), and the resultant solution was charged with di-tert-butoxydicarbonate (9.13 g). The solution was stirred at room temperature for 2 hours and then left to stand at room temperature overnight. The reaction solution was added water, extracted with ethyl acetate, washed with water and saturated brine in that order, and then dried over anhy-



drous sodium sulfate. The solvent was evaporated, and the resultant residue was purified by silica gel column chromatography (hexane:ethyl acetate=2:1) to obtain the target product (13.0 g) as a colorless oil.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>, 400 MHz): δ 1.14 (3H, s), 1.42 (9H, s), 1.53-1.74 (3H, m), 1.79-1.92 (1H, m), 2.74 (2H, t, J=7.9 Hz), 3.58-3.69 (2H, m), 4.05 (1H, br s), 4.57 (1H, br s), 7.20-7.22 (2H, m), 7.38-7.50 (4H, m), 7.54 (1H, s).

ESIMS (+): 504 [M+H]<sup>+</sup>.

#### Examples 43 and 44

(+)-2-t-butoxycarbonylamino-5-[2-chloro-4-(3-trifluoromethylphenylthio)phenyl]-2-methylpentan-1-ol and (-)-2-t-butoxycarbonylamino-5-[2-chloro-4-(3-trifluoromethylphenylthio)phenyl]-2-methylpentan-1-ol

The compound of Example 42 was subjected to optical resolution using high performance liquid chromatography (CHIRALCEL OJ-H, hexane:isopropanol:diethylamine=98:2:0.1 (v/v), measurement wavelength: UV 278 nm, flow rate: 1.0 mL/min). From the pre-elution portion, an [α]<sub>D</sub><sup>25</sup>+15.08 (c 0.63, CHCl<sub>3</sub>) colorless oil was obtained (Example 43), and from the post-elution portion, an [α]<sub>D</sub><sup>26</sup>-13.91 (c 0.63, CHCl<sub>3</sub>) colorless oil was obtained (Example 44).

#### Example 45

(-)-2-Amino-5-[2-chloro-4-(3-trifluoromethylphenylthio)phenyl]-2-methylpentan-1-ol hydrochloride

The compound of Example 43 was reacted in the same manner as in Example 26 to obtain the target product as a white powder.

ESIMS (+): 404 [M+H]<sup>+</sup>.

Optical Rotation: [α]<sub>D</sub><sup>25</sup>-4.48 (c 1.00, CHCl<sub>3</sub>).

#### Test Example

Effect on SCID CD4<sup>+</sup> CD45RB<sup>high</sup> T Cell Transfer Colitis Model

SCID CD4<sup>+</sup> CD45RB<sup>high</sup> T cell transfer colitis model has been reported as a model resembling to Crohn's disease due to its histopathological characteristics and the produced cytokines (Powrie F et al, Immunity, 1, 553-562, 1994). In addition, this model has also been used for evaluation of a

medicine which is used in the treatment of inflammatory bowel disease and its effectiveness has been reported (Liu Z et al., J. Autoimmun., 29, 187-194, 2007).

C.B-17/Icr-scid/scid Jcl (SCID mice) (female, 8 weeks of age, mouse to be transferred) and BALB/c Cr Slc (BALB/c mice) (female, 8 weeks of age, mouse for transfer cell preparation) were obtained and used in the test. CD4<sup>+</sup> CD45RB<sup>high</sup> T cells (naive T cells) prepared from the spleen of BALB/c mice were transferred intraperitoneally into the SCID mice at a concentration of 3×10<sup>5</sup> cells/body, and then colitis was induced by breeding it for 4 weeks. Preparation of the CD4<sup>+</sup> CD45RB<sup>high</sup> T cells was carried out in accordance with the method of Uraushihara et al. (J. Immunol., 171, 708-716, 2003) and FACS Aria Cell Sorter (Becton Dickinson Japan) was used as a cell separator.

The compound produced in Example 27 (compound 27) was dissolved in distilled water and orally administered at doses of 0.3 mg/kg, 1 mg/kg and 3 mg/kg, once a day for 4 weeks starting on the preceding day of cell transfer. Distilled water alone was administered to the vehicle group. Body weight was determined every day during the administration period. The change ratio (%) of the body weight on the determination day was calculated based on the body weight on the day of the start of administration. On the next day of final administration, blood was collected and the large intestine was extracted. The total number of leukocytes was measured using the collected blood. After fixing the extracted large intestine with formalin, tissue sections were prepared and hematoxylin-eosin staining was carried out. Evaluation was performed in accordance with the scoring system (Uraushihara K et al., J. Immunol., 171, 708-716, 2003). That is, the large intestine was roughly divided into 3 regions (proximal region, middle region and distal region), and scoring was carried out on the 3 layers, which are mucosa, submucosa and muscularis, of each region. By totaling the obtained scores of each region, the value having the highest total score among the three regions was used as the score of the individual. The change ratio of the body weight and the total number of leukocytes were shown by mean±standard error and the pathological score was shown by median.

As shown in Table 1, body weight loss and the total number of leukocytes were significantly suppressed by the administration of compound 27 in comparison with the vehicle group. In addition, suppressive effect was found regarding the pathological score. From these results, it was revealed that the compound 27 shows the suppressive effect on the SCID CD4<sup>+</sup> CD45RB<sup>high</sup> T cell transfer colitis model.

TABLE 1

Test group	Change ratio of body weight (%)		Total number of leukocytes (cells/μL)	Pathological score
	On the third week	On the fourth week		
Vehicle group	-5.2 ± 1.9	-7.6 ± 1.6	3211 ± 393	7
Compound 27 (0.3 mg/kg)	1.1 ± 1.4 **	-1.0 ± 2.2	2733 ± 561	5
Compound 27 (1 mg/kg)	1.5 ± 0.8 **	-1.4 ± 2.0	1980 ± 241	5
Compound 27 (3 mg/kg)	0.5 ± 1.2 *	-0.8 ± 2.0 *	1720 ± 327 *	3.5

The number of animals: 8 to 10

\* <0.05 vs vehicle group (Dunnett's test)

\*\* <0.01 vs vehicle group (Dunnett's test)

## 39

## Formulation Example

Composition	
Compound 27	0.1 mg
D-mannitol	247.5 mg
Magnesium stearate	2.5 mg

A mixed powder was produced by mixing the compound 27 with D-mannitol and further mixing magnesium stearate therewith. A capsule preparation was produced by filling this mixed powder in a capsule.

## INDUSTRIAL APPLICABILITY

It became possible to provide a pharmaceutical which is useful for the treatment or prevention of inflammatory bowel disease by the compound of the invention.


The invention claimed is:

1. A method of treating an inflammatory bowel disease, the method comprising administering to a patient in need thereof, an effective amount of a (R)-2-amino-5-[2-chloro-4-(3-trifluoromethylphenylthio)phenyl]-2-methylpentan-1-ol, or a pharmaceutically acceptable salt thereof.

2. A method of treating an inflammatory bowel disease, the method comprising administering to a patient in need thereof, an effective amount of a (-)-2-amino-5-[2-chloro-4-(3-trifluoromethylphenylthio)phenyl]-2-methylpentan-1-ol, or a pharmaceutically acceptable salt thereof,


wherein the (-)-2-amino-5-[2-chloro-4-(3-trifluoromethylphenylthio)phenyl]-2-methylpentan-1-ol, or a pharmaceutically acceptable salt thereof, is obtained by:

allowing a compound represented by formula (2) and a compound represented by formula (10) to react with each other in the presence of a base,



(2)

wherein R<sup>1</sup> represents a trifluoromethyl group, R<sup>2</sup> represents a chlorine atom, A represents a halogen atom, X represents a sulfur atom, and n denotes 3,



(10)

## 40

wherein R<sup>3</sup> represents a methyl group and R<sup>4</sup> represents an alkyl group having 2 carbon atoms,

subjecting a resultant product to acidolysis,

protecting a nitrogen atom with a t-butoxycarbonyl group, reducing a resultant protected compound, and


deprotecting the nitrogen atom of a resultant reduced compound.

3. A method of treating an inflammatory bowel disease, the method comprising administering to a patient in need thereof, an effective amount of a (-)-2-amino-5-[2-chloro-4-(3-trifluoromethylphenylthio)phenyl]-2-methylpentan-1-ol or a pharmaceutically acceptable salt thereof.

4. A method of treating an inflammatory bowel disease, the method comprising administering to a patient in need thereof, an effective amount of a (R)-2-amino-5-[2-chloro-4-(3-trifluoromethylphenylthio)phenyl]-2-methylpentan-1-ol, or a pharmaceutically acceptable salt thereof,


wherein the (R)-2-amino-5-[2-chloro-4-(3-trifluoromethylphenylthio)phenyl]-2-methylpentan-1-ol, or a pharmaceutically acceptable salt thereof, is obtained by:

allowing a compound represented by formula (2) and a compound represented by formula (10) to react with each other in the presence of a base,



(2)

wherein R<sup>1</sup> represents a trifluoromethyl group, R<sup>2</sup> represents a chlorine atom, A represents a halogen atom, X represents a sulfur atom, and n denotes 3,



(10)

wherein R<sup>3</sup> represents a methyl group and R<sup>4</sup> represents an alkyl group having 2 carbon atoms,

subjecting a resultant product to acidolysis,

protecting a nitrogen atom with a t-butoxycarbonyl group, reducing a resultant protected compound, and

deprotecting the nitrogen atom of a resultant reduced compound.

\* \* \* \* \*